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Reporting systems for adverse reactions or adverse events associated with blood transfusion 
arose in Europe in the aftermath of public outcry following the contaminated blood scandals 
and legal cases of the 1980s and 1990s. Hemovigilance can be defined as ‘a set of surveillance 
procedures covering the whole transfusion chain from the collection of blood and its 
components to the follow-up of its recipients, intended to collect and assess information on 
unexpected or undesirable effects resulting from the therapeutic use of labile blood products, 
and to prevent their occurrence and recurrence’.1 The first hemovigilance systems, those in 
France and in the United Kingdom, are quite different from each other.2,3 SHOT (Serious 
Hazards of Transfusion) in the UK requests the reporting of “all serious hazards” whereas 
in France it is mandatory to report all adverse transfusion reactions and transfusion errors, 
regardless of severity of patient morbidity and the relationship (imputability) to transfusion. 
(Brief descriptions of the French hemovigilance system and SHOT are given in Annexes 1 and 2 
to this chapter.) Countries outside Europe have followed suit – the Quebec province in Canada 
was among the early uptakers and developed a comprehensive system similar to the French 
but based within the public health structures and on a voluntary basis.4 In The Netherlands 
a recommendation on hemovigilance was issued by the Blood Transfusion Advisory Council 
(College voor Bloedtransfusie of the – then – 22 Red Cross Blood Banks) in 1997 but it was not 
till 2002 that the TRIP (Transfusion Reactions In Patients) Dutch National Hemovigilance Office 
became functional. The Dutch Hemovigilance Office is run by an independent foundation 
which is governed by representatives of professional bodies. In this aspect it is modelled on 
SHOT, however it collects reports of all severity levels of transfusion reactions as well as errors 
and incidents including near miss (see www.tripnet.nl and Annex 3).
Since 2005 European Union (EU) legislation has mandated that member states must have a 
system for receiving and registering reports of serious adverse reactions and serious adverse 
events relating to quality and/or safety of blood or components for transfusion.5 A serious 
adverse reaction is defined as ‘an unintended response in donor or in patient associated with 
the collection or transfusion of blood or blood components that is fatal, life-threatening, 
disabling, incapacitating, or which results in, or prolongs, hospitalisation or morbidity’. A 
serious adverse event is defined in the directive as ‘any untoward occurrence associated with 
the collection, testing, processing, storage and distribution, of blood and blood components 
that might lead to death or life-threatening, disabling or incapacitating conditions for patients 
or which results in, or prolongs, hospitalisation or morbidity’. The latter definition is at variance 
with usage of ‘adverse event’ in the setting in clinical studies since it denotes an error or 
untoward occurrence (incident) irrespective of whether there was actual patient harm. When 
the legislation came into force the existing hemovigilance systems made modifications where 
necessary in order to ensure compliance. Other countries had to create systems de novo. The 
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European legislation also requires the submission of an annual overview of serious adverse 
reactions and serious adverse events to the European Commission according to specified 
definitions. The serious adverse reactions are to be listed according to their imputability, i.e. 
the likelihood that they can be ascribed to the blood or blood component. Also the definite 
and probable cases are to be listed separately according to whether there was a link with the 
quality and/or safety of the blood component (e.g. when an infection is transmitted). To date 
the collected information has been publicly presented by Commission representatives at a 
number of symposia in anonymous fashion as to the countries which submitted the data 
and with the explicit statement that the reporting so far must be seen as a learning exercise. 
Variations have been seen between country data but it has not been possible to examine 
possible explanations.
Survey
For hemovigilance to be an instrument for improving safety of blood transfusion, it must be 
based on quality-assured data. The value of data for comparisons, benchmarking and trending 
depends firstly on the coverage: have all relevant organisations contributed information and 
if not, is it known which proportion of national blood use is covered? Secondly, have the 
reactions and events been assessed according to the same criteria and can this assessment 
be verified? For instance, did all the reports of TRALI (Transfusion-related acute lung injury) 
in a country meet certain criteria? These two quality aspects have an obvious impact on the 
number of events which will be reported in a particular category. We performed a simple 
descriptive survey of whether the data collected by the European national hemovigilance 
systems are validated as to completeness of coverage and capture information by which the 
type of reaction may be verified.
methods
The mandatory European reporting is laid down in the European Directives 2002/98/EC and 
2005/61/EC. Briefly, blood establishments are required to report serious adverse reactions and 
events which may be attributable to the quality and safety of blood and blood components to 
the national competent authority for blood. Hospitals must report to the blood establishment 
if a serious reaction or event may have a relation to component quality or safety; they may 
also report directly to the competent authority. A non-binding guidance document has been 
provided to assist countries in their data classification,5 which includes the International Society 
of Blood Transfusion (then still in draft form) definitions for the non-infectious transfusion 
reactions and the SHOT definition for transfusion-transmitted infection.6,7
We sent hemovigilance contact persons from the national competent authorities a short 







documentation of coverage, validation of report types and outputs. If the reply was supplied by 
a different person, this was accepted providing that the intended responder was in agreement, 
as documented by email “copying-in”.
ReSuLTS
Response and organisation of hemovigilance systems
Responses were received from 23 out of the 27 (85%) European Union member states. Nine 
responding countries created their national hemovigilance system subsequent to the Directive. 
Three countries made major changes to previous activity in order to become compliant. In 
seven the reporting of serious adverse reactions and events became mandatory while in four 
there was already mandatory reporting as required under the Directive. The system is directly 
run by the competent authority in 17 countries and by a separate organisation and/or the 
blood establishment(s) in six. In four responding countries a separately run non-mandatory 
system exists which feeds information to the mandatory system to a varying extent. Table 1 
summarises basic characteristics of the reporting systems.
Documentation of coverage
In five responding countries there is a single national blood establishment. Out of the 18 
countries with multiple blood establishments, seven confirmed that all submitted reports. 
Eight received reports from median 80% (range 25 – 90%) of blood establishments and 
confirmation of “nil to report” or activity levels from the others. In three responding countries it 
was not known what percentage of blood establishments participated. 
Four of the 23 countries state that 100% of hospitals contributed reports or confirmed nil to 
report. Ten specify that median 76% (range 47 – 96%) of hospitals provided information while 
nine systems do not know what percentage of hospitals participated. 
Assessment of reported data and outputs
In 12 responding countries (52%), supporting data were supplied with all (eight countries) or 
only serious reports (four countries). This data, it was confirmed, could lead to modification of 
event type. In eleven countries most or all reports are accepted without verification. In eighteen 
(78%) countries the hemovigilance system makes a public report of aggregate findings. Ten 




Discussion of the survey findings
This mini-survey showed that the legislation has resulted in all the responding countries 
having an established national hemovigilance system. The majority but not all of the systems 
(87%) document the participation level of blood establishments and only 14 countries (61%) 
document the coverage of hospitals. Usefulness of the data for comparisons can be improved 
if all systems document the participation of reporting organisations and the coverage of the 
total distributed blood components so that this can be taken into account.
Table 1 Characteristics of national hemovigilance systems broken down by organisation of blood 
supply
Characteristic of hemovigilance 
system
Responding countries
































































a A blood establishment (BE) is an organisation which performs collection, testing and/or processing of blood or 
blood components, i.e. hospital blood transfusion laboratories which themselves perform secondary processing 
such as irradiation of blood components must be licensed as blood establishments even if they do not perform 
collection and donor testing. 
In twelve countries the hemovigilance system receives supporting information with at least 
the serious reactions so these can be verified. In practice the assessment of reports is not 
easy; not infrequently the category is modified from the original reporting category. In our 
opinion, external expert review of serious reports should be formally included by all systems 
prior to preparation of annual reports. Communicating the review panel’s advice to reporting 







showing that the reports are taken seriously by the receiving body. This practice is in place in 
at least six systems.
Eighteen out of the 23 responding countries annually publish the findings. Additionally, five 
respondents commented that data are presented in national or regional meetings. Public 
reporting is desirable because it provides transparency and knowledge of documented risks. 
Moreover public reporting will encourage participation and ensure that any recommendations 
for improvement are heard by those who are involved in the transfusion “chain”. 
Commendably, the European Commission representatives have consistently asserted that 
the reporting is a learning exercise and that the hemovigilance reporting systems should first 
and foremost be useful for the countries themselves. For future data collection exercises, the 
Commission could improve annual reporting by modifying the reporting form to include the 
percentage of reporting establishments which supplied information and the percentage of 
national blood use that is covered.1 
A strength of this study is the high response rate of 23 out of 27 countries, which is remarkable 
for a non-mandatory survey. However the brevity of the questionnaire constitutes a limitation, 
for instance it did not capture details about how the system communicates with those who 
submit reports, nor of methods of assessing adverse event (error and incident) reports. Another 
limitation is that it was impossible to assess the level of compliance of physicians and other 
professionals within reporting establishments.
In summary, our survey of European Union member states’ hemovigilance systems found that 
nine out of 23 responding systems started as a consequence of the legislation which rendered 
reporting mandatory. Currently the coverage is not always documented and almost half of the 
systems do not routinely verify the serious reports. These aspects should be included in the 
ongoing efforts to improve reporting.
Final conclusion of the survey and introduction to the thesis question
In our mini-survey we considered quality aspects of the collected data within different European 
hemovigilance systems and found that there is room for improvement as regards documenting 
coverage and validating the types of reported event. The Dutch hemovigilance system meets 
these basic quality criteria: the coverage is documented and has run at approximately 96% of 
hospitals since 2006. Its procedures include expert review of all serious reports; findings have 
been published.6 
1 These features were included in the form for the 2012 reporting exercise, circulated in July 2012
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Hemovigilance reporting is regarded as the norm in Europe as well as in many non-European 
countries. The stated objective of collecting hemovigilance data is to analyse the reported 
adverse reactions and events and make recommendations for improving transfusion safety. 
This has prompted the study question of this thesis: after ten years of national hemovigilance 
activity in The Netherlands, can we say that it has made a difference to transfusion safety?
In the first part of the thesis we focus on donor vigilance and the safety of those who donate 
blood or hematopoietic stem cells. Chapter 2 introduces this section with a description of 
recent developments in studying blood donor complications and their prevention. Chapter 
3 studies risk factors for various donor complications and collection problems at first whole 
blood donation in comparison to repeat donors, and examines the impact of these problems 
on donor return. In chapter 4 we present a study of short-term safety in a cohort of related 
healthy donors who underwent G-CSF mobilisation and collection of peripheral blood stem 
cells by hemapheresis and also consider whether there is any indication of long-term increased 
risk of malignancy or cardiovascular events. 
The second part of this thesis considers topics from recipient hemovigilance. Chapter 5 uses 
the reports to TRIP as the basis for a case-control study of risk factors for the most common 
type of report, that of new allo-antibodies. In chapter 6 we study the effect of the intervention 
of introducing male-only plasma for transfusion in order to reduce the risk of TRALI. Chapter 
7 collates information from several years of national hemovigilance reporting to examine the 
question: do hospitals with a relatively high incidence of reported transfusion reaction have 
fewer reports of incorrect blood component transfused, i.e. do they appear to be safer? 
The final chapter gives an overview of the reported studies and considers whether they have 
demonstrated a beneficial effect of hemovigilance on transfusion. The discussion will also 
reveal directions in which future development of hemovigilance activity can open up further 
prospects for improving safety for donors or recipients of blood or blood components.
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ANNex 1 THe FReNCH HemovIgILANCe SySTem
(reference 1 and http://ansm.sante.fr/Produits-de-sante/Produits-sanguins-labiles)
Hemovigilance was introduced as a mandatory activity in 1994. From the beginning, all 
severity levels of transfusion reaction were included, as well as all degrees of imputability to 
the transfusion. 
In each of the approximately 1500 hospitals or clinics which perform blood transfusions a 
physician is responsible for hemovigilance reporting (hemovigilance correspondent) and 
ensuring compliance with regulations concerning blood transfusion. In France, pre-transfusion 
blood testing and crossmatching are generally performed by the Établissement de Transfusion 
Sanguine (ETS) of the blood service (Établissement Français du Sang, EFS). The hemovigilance 
correspondent of the ETS coordinates the necessary additional investigations following a 
transfusion reaction. The third actor at the local/regional level is the regional hemovigilance 
coordinator at the regional health agency (coordonnateur régional d’hémovigilance, CRH), 
who oversees compliance with regulations in the region and follows up on actions taken 
by hospital transfusion committees following a reported transfusion error. The hospital 
hemovigilance correspondent, the ETS hemovigilance correspondent and the regional 
hemovigilance coordinator all verify the details of a hemovigilance report and sign it off in the 
digital reporting system (e-fit, taken into use in 2004). 
At the national level, the role of the competent authority was assumed by the hemovigilance 
department at the Agence française de sécurité sanitaire de produits de santé, Afssaps, until 
May 2012. This has now been replaced by the Agence nationale de sécurité du médicament 
et des produits de santé, ANSM. The staff of the competent authority can add queries to the 
reports in the e-fit database, as can staff from the central hemovigilance department of the 
EFS. The Afssaps/ANSM publishes an annual hemovigilance report (available on the website) 
based on all reports of which the investigations have been concluded. The EFS also compiles 
a report; because e-fit is a real-time database the figures may differ depending on the date of 
downloading. The overall level of reported transfusion reactions was 3.0 per 1000 units issued 
in 2000 and has gradually declined to 2.5 in 2010. Variation in reporting level is noted between 
the regions and between individual hospitals. A decline in ABO-incompatible red blood cell 
transfusions has been observed since approximately 2000 (discussion in Chapter 7).
Important themes have been addressed by national working parties of professionals who 
work with Afssaps/ANSM staff to develop new forms and guidance documents. These themes 
include allergic transfusion reactions, TRALI and transfusion-associated circulatory overload 







generally introduced through ministerial circulars. At the time of writing the full effect of the 
restructuring of the national competent authority and the new arrangements regarding the 
working groups are not yet clear. 
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ANNex 2 SHoT (SeRIouS HAzARDS oF TRANSFuSIoN), uNITeD kINgDom
(Reference 2 and www.shotuk.org)
The SHOT scheme was launched in 1996. It is run by a steering group comprised of representatives 
of professional bodies involved with blood transfusion. The scheme captures reports on serious 
reactions or errors/incidents associated with transfusion of blood components or with the use 
of anti-D. The SHOT reporting scheme is voluntary in principle but professionally mandated. 
Practitioners in hospitals submit an initial report, about which additional details are requested 
using a further questionnaire which is specific to on the type of reaction or event which has 
been reported.
With the advent of the obligation under EU legislation to report serious adverse reactions and 
serious adverse events, these serious reports have been collected by the competent authority, 
the Medicines and Healthcare Products Regulatory Agency (MHRA). An online reporting 
system, SABRE (Serious adverse blood reactions and events), was introduced to facilitate 
reporting to SHOT and/or MHRA as appropriate. Dendrite, an improved reporting module for 
SHOT and/or MHRA reports, became operational in 2010. 
SHOT received reports from 95% of NHS organisations in 2010. Each year a hemovigilance 
report is published under the responsibility of the SHOT steering group. The reports incorporate 
multiple learning points and recommendations for practice. Through the years, SHOT has 
particularly highlighted the hazards of incorrect transfusions and, more recently, incidents 
leading to inappropriate and unnecessary transfusion. Near miss reports were analysed for the 
first time in the 2010 annual report. As the scope of reporting has widened, the annual total 
number of reports has gradually increased from 0.13 per 1000 units distributed in 2001-2 to 
approximately 1.0 per 1000 in 2011. A decline in ABO-incompatible red blood cell transfusions 
has been observed since approximately 2004 (discussed in chapter 7).
In the years during which SHOT has been operational, a series of Department of Health 
(governmental) Better Blood Transfusion circulars (1998, 2002, 2007) have issued 
recommendations on blood transfusion laboratory and clinical transfusion practice. In 
hospitals, transfusion practitioners have an important role in overseeing transfusion practice 
and staff training. The hospital transfusion team (generally a subgroup of a larger hospital 
transfusion committee) assesses hemovigilance reports and leads actions to monitor and 
improve transfusion safety. The report “An organisation with a memory” (2000) by a Department 








ANNex 3 TRIP DuTCH NATIoNAL HemovIgILANCe oFFICe (www.TRIPNeT.NL)
TRIP (Transfusion Reactions In Patients) Foundation was founded in 2001 by representatives 
of the various professional organisations involved in the field of blood transfusion. Since 
December 2002, the TRIP National Hemovigilance Office has managed the national reporting 
system for transfusion reactions in collaboration with contact persons in the hospitals and 
the blood service, Sanquin Blood Supply (Sanquin Bloedvoorziening). Reporting to TRIP is 
anonymous and voluntary in principle. Participation is considered the norm by the Healthcare 
Inspectorate (IGZ) and the national “CBO” blood transfusion guideline. 
TRIP receives and analyses reports of all levels of severity. The digital reporting form captures 
data on relevant clinical findings and results of investigations and allows for questions and 
provision of additional comment. The TRIP staff assess all reports and communicate with 
the reporters if necessary to verify the stated category, severity grade and imputability of 
(potentially) serious reports. An Expert Committee appointed from the TRIP Governing Board 
assesses all serious reports and a sample of non-serious reports.
Figure 1 shows the communication lines for hemovigilance reporting in The Netherlands. In 
the hospitals TRIP communicates with a regular contact person, the hemovigilance officer who 
is often the chief biomedical scientist in the transfusion laboratory. Most hospitals have also 
appointed transfusion safety officers who prepare the transfusion reaction or incident reports, 
provide training, perform audit etc.
Under the European directive 2002/98/EC there is an obligation to report serious adverse 
reactions and adverse events that may be associated with the quality and/or safety of blood 
components to the competent authority, IGZ. TRIP provides the analysis and reporting of 
these serious (grade 2 or higher) reports on behalf of the IGZ. Hospitals can use the TRIP online 
reporting system to make reports available to the IGZ; this is not automatic but remains the 
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Donor vigilance – what are we doing about it?
Chapter 3 
Risk factors for donor complications at first and repeat whole blood donation: 
cohort study with assessment of the impact on donor return. 
Chapter 4 
Clinical outcomes after peripheral blood stem cell donation by related donors: 
a Dutch single-center cohort study.
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Donor vigilance – 
what are we doing about it?
Johanna C. Wiersum-Osselton
Tanneke Marijt-van der Kreek
Wim L.A.M. de Kort




Donor vigilance is the systematic monitoring of adverse reactions and incidents in blood donor 
care with a view to improving quality and safety for blood donors. Standard international 
definitions are available for surveillance purposes. In recent years advances have been made in 
determining risk factors for vasovagal and other adverse reactions to blood donation as well as 
in evaluating preventive measures. Blood establishments should record all adverse reactions in 
blood donors. Besides its use for individual donor care, this information can be reviewed within 







1. INTRoDuCTIoN: wHAT IS DoNoR HemovIgILANCe?
The impressive advances which have been made in transfusion therapy and in treatments which 
are not possible without transfusion support, are only possible because of voluntary, most 
often unremunerated donation of whole blood or blood components by donors worldwide. In 
recent years awareness has grown of the importance of monitoring safety and quality of care 
for blood donors, both as a professional obligation and in the interests of maintaining public 
willingness to donate. 
Hemovigilance is “a set of surveillance procedures covering the whole transfusion chain from 
the collection of blood and its components to the follow-up of its recipients, intended to collect 
and assess information on unexpected or undesirable effects resulting from the therapeutic 
use of labile blood products, and to prevent their occurrence and recurrence”.1 Donor (hemo)
vigilance is part of this process, and can be defined as the systematic monitoring of adverse 
reactions and incidents in the whole chain of blood donor care, with a view to improving 
quality and safety for blood donors.2 The full term, donor hemovigilance, draws the distinction 
between vigilance concerning blood donors and other donors, for instance stem cell or organ 
donors. For the remainder of this paper, for the sake of brevity we shall refer to donor vigilance. 
Donor vigilance firstly concerns the surveillance of adverse reactions (complications) from 
blood donation and an organized approach to attempting to reduce them as far as possible. 
Donor vigilance should also encompass the systematic recording and analysis of errors 
(incidents) in blood donor care. Additionally, procedures should be in place for handling post-
donation information as well as for donor counseling following unexpected findings, such 
as positive or false-positive test results. In the remainder of this paper the focus will be on 
complications of blood donation.
2. INTeRNATIoNAL ADvANCeS IN DoNoR vIgILANCe
A standard reference list of surveillance definitions for complications of blood donation has 
been developed by the Haemovigilance working party of the International Society for Blood 
Transfusion (ISBT) in collaboration with the International Haemovigilance Network (IHN; 
then: European Haemovigilance Network). This list is available on the websites of the ISBT 
and IHN.3 As well as the definitions for different types of complication, criteria are given for 
severe (serious) complications, which are broadly: hospitalization, life-threatening nature, 
long-term morbidity or fatal outcome. The standard also draws attention to the consideration 
of imputability, the likelihood that an adverse outcome can be attributed to the blood 
donation; critical assessment of the imputability is particularly relevant for events which did 
not immediately follow the donation (e.g. a heart attack several days after donating). For the 
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sake of international collaboration, it is desirable for countries to ensure that their definitions 
are the same as, or can be mapped to, the international definitions.
There is increased interest in reporting, treating and attempting to reduce complications of 
blood donation. Table 1 presents selected findings from a number of recent studies reporting 
rates of vasovagal reaction and risk factors. Of note, it is seen in large datasets that the risk 
of a vasovagal reaction is increased in female donors, younger and first-time donors as well 
as donors with lower blood volume as estimated from height and body weight.4,5 Delayed 
vasovagal reactions are a particular cause for concern because they occur off site and are 
more likely to lead to accidents; these have been found to be associated with female sex and 
lower estimated blood volume.6 A water drink before donation, use of applied muscle tension 
and social support during donation have been found effective in reducing minor vasovagal 
reactions and/or increasing likelihood of donors returning for subsequent donations.7-9 
In these intervention studies use is commonly made of an inventory questionnaire so that 
occurrence of milder reactions can be studied, using smaller groups because of the higher rate 
of occurrence.10 
3. INTeRNATIoNAL SuRveILLANCe DATABASe FoR TRANSFuSIoN-
ASSoCIATeD ReACTIoNS AND eveNTS (ISTARe)
At the initiative of the IHN and in collaboration with the ISBT Haemovigilance working party, an 
international surveillance database is under development for transfusion-associated adverse 
reactions and events. The database also captures information on blood donation complications. 
Pilot rounds of data collection have collected data from 2006 up to and including 2009; over 15 
national hemovigilance systems have participated in one or more of these rounds. It is hoped 
that online data collection will take place in the autumn of 2011 for the first time.1 
Not all participating countries have been able to provide data on complications of blood 
donation: this rose from 6 out of 11 (54%) for 2006 to 11 out of 17 (65%) for 2009.11 Because the 
rates of complications differ appreciably between whole blood donation and apheresis, data 
are submitted separately if this is possible; however not all countries are able to differentiate 
between donation types and levels of severity of complications. In the data considerable 
variation is seen between national rates of recorded donation complications. For instance, 
the median rate of vasovagal reactions (faints and pre-faints taken together) to whole 
blood donation in 2009 was 4.1 per 1000 (6 countries) and ranged from 0.05 to 10.6; serious 
vasovagal complications were reported with a median rate of 0.06 per 1000 collections (range 
1   Note (November 2012) This took place; results presented by C. Politis at International Haemovigilance 







0-0.3, whole blood and apheresis taken together) by 9 countries. Local complications, 
predominantly hematomas, were reported at a median rate of 1.1 per 1000 for whole blood 
donation and apheresis combined (range 0.04 to 5.9; 11 countries).
Table 1. Rates of vasovagal reactions and risk factors described in recent publications
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donation




9 countries supplied data
Sorensen  
200820
41274 4.0 (3.43-4.63) Aarhus region in Denmark





14% of donors aged 16-19 yrs.






Risk factors (univariate) 
17-18yrs2: OR 4.19 (3.94-4.45) 
Female: OR 2.21 (2.09-2.35) 
1st donation: OR 2.80 (2.66-2.94)
Kamel 200915 793,293 4.2 (4.0-4.3) 5.2 (5.0-5.4) “Moderate and severe”
NL July – Dec 2010 436,571 5.5 (5.3-5.7) 6.0 (5.7-6.3) [Unpublished data]
VVR = vasovagal reactions per 1000 collections
# median, range of national rates
$ reactions with loss of consciousness, prolonged recovery or injury
1 reference group: 20 years and older
2 reference group: 25 to 65 years 
The progressive improvement in availability of data is encouraging but the large differences 
in reported rates in the pilot data need to be examined further. They may be partly explained 
by differences in procedures, for instance the volume drawn, is it adjusted according to donor 
size, is intravenous volume replacement given. Differences in completeness of reporting are 
also likely. Future discussion between national reporters on the nature and quality of the 
information should assist in achieving better comparability of data.
4. DoNoR vIgILANCe IN THe NeTHeRLANDS: ImPLemeNTINg AN ImPRoveD 
CoDINg SySTem FoR ReCoRDINg ComPLICATIoNS oF BLooD DoNATIoN
In The Netherlands over 500,000 whole blood collections and 340,000 apheresis procedures 
(plasma and platelets) are performed annually, from a total of nearly 400,000 volunteer donors. 
The national code list for donor complications was revised in order to record more details and 
cover new procedures such as Rhesus immunisations. 
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After staff training in the autumn of 2009, the revised codes were introduced by administrative 
region during the first half of 2010. Following implementation, staff received feedback on 
wrongly used codes and were asked to correct them. Data were extracted from the blood 
service information system (eProgesa version 5.0.2, Mak-System International Group, Paris, 
France) for analysis. We performed a before-and-after comparison of routinely recorded 
information.
The overall rate of recorded donor complications increased. For instance, the rate of recorded 
vasovagal reactions (faints and prefaints) was 0.46 per 100 whole blood collections in 
2009 and rose to 0.60 per 100 in the second half of 2010 [unpublished data]. There were 
no changes in donor demographics or procedures to explain such a rise so we conclude it 
is most likely the result of improved recording. Using the new codes, rates of specific (sub)
types of donor complications can be calculated; causes of failed collections and product loss 
in the collection centres can be analysed using the same data. The recorded complications 
and procedural problems have been reviewed with a view to developing specific projects to 
reduce complications and reduce rates of unsuccessful procedures. The improved recording 
also opens opportunities for scientific analysis, international comparisons and benchmarking. 
Additional improvement measures which have been undertaken by Sanquin include revision 
of the SOP for venepuncture performance which now cautions explicitly against needle 
manipulation and repeated stabs if puncture is not immediately successful. Recertification 
in skin cleansing and venepuncture technique has been introduced. Extra precautions have 
been implemented to further reduce the risk of mix-up of saline and citrate solutions during 
apheresis procedures. 
5. CHALLeNgeS FoR DoNoR vIgILANCe
As described above, international collaboration and comparison of data open possibilities 
for benchmarking and hypothesis generation for further research. Furthermore, data sharing 
is the only way to advance knowledge of very low-frequency events, such as needle injury 
associated with long-term morbidity. For all data comparisons, use of common definitions is 
essential. Nevertheless, there are still differences between countries and blood establishments 
in types of collection procedures, volumes collected etc. 
There are several challenging areas. One of these is that of iron depletion, particularly but not 
exclusively in whole blood donors. It is well established that repeated phlebotomy reduces 
iron stores, demonstrated by lower serum iron or ferritin levels12,13 even within guidelines for 







a maximum of three whole blood donations per year for women, five for men and always a 
minimal interval of 56 days). This leads to deferrals because of hemoglobin (or hematocrit 
or other screening test) and in some cases frank anemia for which iron supplementation 
treatment is required. Recent studies have started to assess the possible place of serum 
ferritin determination as a tool to monitor and improve the iron status of at-risk donors.14 
For donors who repeatedly fail the hemoglobin screen, the interval between donation can 
be extended and some donors may opt for plasmapheresis instead of whole blood donation. 
A recent Sanquin study has evaluated predictive factors for hemoglobin deferrals, so that 
donation intervals could in future adjusted pre-emptively.15 Meanwhile it remains less clear 
what, if any, are the health consequences of depleted iron stores for asymptomatic healthy 
donors who maintain their hemoglobin levels. Some blood establishments favour oral iron 
supplementation (replacement) for some or all donors. Objections raised by others include 
the risk of masking iron loss caused by pathologies or of toxicity following accidental ingestion 
of the medication, as well as the consideration that volunteer donors should not be asked to 
take medication with the attendant risk of side effects. Further work is needed in this area to 
improve the evidence base for donor management recommendations; national policies will 
need to take account of local factors such as availability of donors and dietary patterns.
Another challenging area is that of possible long-term complications of repeated apheresis 
procedures: might development of osteoporosis be accelerated? Frequent plasmapheresis is 
associated with lower immunoglobulin content of the products.16 Might repeated removal of 
plasma lead to depletion of immune capacity? It is important that further research is undertaken 
and published in these areas so that evidence-based measures can be implemented to 
safeguard donors’ health.
Concern has been expressed about whether it is wise to publish information about 
complications of blood donation. Might it not put off potential blood donors and threaten the 
blood supply? This concern can be countered by a firm statement that it is an ethical obligation 
to be open and transparent about the occurrence of complications. This information should 
be supplied to donors before their donation, so that truly informed consent is obtained. If 
blood services take this responsibility seriously, they will ensure that balanced information 
is available. This information can incorporate recent knowledge about methods of reducing 
complications. Donors will thus be empowered and enabled to prepare adequately for 
their donation, thereby reducing the risk of complications and increasing their likelihood of 
becoming committed regular donors.17 
In conclusion, the last years have seen advances in monitoring and studying the occurrence 
and prevention of complications of blood donation. It is recommended that all blood services 
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adopt a systematic approach to monitoring the rates of donor adverse reactions, in the 
interests of improving donor care.18
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First-time donation is among recognized risk factors for vasovagal reactions (VVR) to blood 
donation and reactions are known to reduce donor return. We assessed associations between 
potential risk factors and VVR and needle-related complications at first-time whole blood 
donation in comparison to repeat donation and analysed the impact of complications on 
donor return.
Study design and methods
We performed a cohort study on whole blood donations in The Netherlands from 1-1-2010
to 31-12-2010 using data extracted from the blood service information system. Donation 
data till 31-12-2011 were used to ascertain donor return.
Results
In 2010 28,786 donors made first whole blood donations and there were 522,958 repeat 
donations. VVR occurred in 3.9% of first donations by males and 3.5% of female first-time 
donations compared to 0.2% and 0.6% respectively of repeat donations. Associations of VVR 
with other factors including age, body weight, systolic and diastolic blood pressure were similar 
in first-time versus repeat donors. Needle-related complications occurred in 0.2% of male and 
0.5% of female first-time donations and in 0.1% and 0.3% respectively of repeat donations. 
Among first-time donors, 82% returned within one year following uncomplicated first donation 
and this was 55% and 61% respectively following VVR and needle-related complications; these 
percentages among repeat donors were 86%, 58% and 82%. 
Conclusion
Among first-time donors, females suffered less from VVR than males. Other risk factors had 
similar associations among first-time and repeat donors. VVR and needle-related complications 
at first as well as subsequent donation are followed by reduced donor return.







In the last two decades the occurrence of adverse reactions to whole blood donation and 
component apheresis has been increasingly studied1-3. Suggested risk factors for vasovagal 
reactions (VVR) include young age, low body weight or small size (small estimated blood 
volume), female sex and first-time donor status4-8. 
The occurrence of an adverse reaction reduces the likelihood of a donor returning and 
becoming a repeat donor9-12. It is important for blood centers to minimize donor complications, 
particularly at the first donation, in the interests both of donor safety and of maximizing the 
number of returning donors. 
Hitherto most studies of risk factors have analysed first-time status as one among various 
parameters. This does not answer the question of whether the risk factors are the same for first-
time donors and repeat donors. Analyses of risk factors among first-time donors for donation 
complications have been performed only for a limited number of parameters13. We examined 
risk factors among first-time whole blood donors in 2010 for the occurrence of vasovagal 
reactions, local needle-related complications or procedural problems in comparison to repeat 
donors, and assessed the impact of the different types of donation problems on donor return. 
mATeRIALS AND meTHoDS
Study design and population
We performed a cohort study including all first-time and repeat whole blood donations in 2010. 
Records of whole blood and plasmapheresis attendances to the end of 2011 were examined to 
evaluate the impact of problems at the index donation on donor return. 
Data extraction
We extracted data from existing databases on all whole blood donations in 2010 including 
recorded donor complications and procedural problems. Parameters included collection center 
(fixed site or mobile site), donor age, sex, donation type, month, pre-donation hemoglobin (Hb) 
and blood pressure, successful (≥ 450ml) or incomplete collection, time of day, donor height 
and weight; however the height and weight were not obligatory data in 2010 and 2011 so are 
not known for all donors. Data on daily outdoor maximum temperature in the center of the 
country were downloaded from the national meteorological institute website. In addition, all 
donor complication reports into the national quality management database were examined. 
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For each donor we determined whether they had returned for screening and potential donation 
within one year (whole blood or plasmapheresis). We also noted whether the donor had been 
deferred permanently before a subsequent donation and the coded reason for deferral. For all 
donors who made their subsequent whole blood donation up to the end of 2011, we extracted 
information on whether this donation had been successful and what donor complication or 
collection problem, if any, was recorded.
Setting: blood supply organisation
In the Netherlands there has been a national, non-commercial blood service since 1998. All 
donations are from volunteer non-remunerated blood donors. At their first attendance they are 
interviewed and a sample is given for testing; the first donation takes place on a subsequent 
visit. At this intake interview, body weight and height are recorded, hemoglobin level and 
blood pressure are measured and venous accessibility is assessed. Blood donation is permitted 
from age 18 up to and including 69 years (new donors must be < 65 years); body weight must 
be above 50 kg. All donor, donation, testing, processing and distribution data are recorded in 
the blood service computer system (e-)Progesa (MAK systems, Paris, France). 
Whole blood donors are sent invitation cards according to supply needs. (Walk-in attendances 
of registered donors provide a small minority of collections.) Women may donate up to three 
times a year, men up to five times – all donors donate the standard volume of 500 ml plus 
test samples, in total not exceeding 550 ml. A donor physician is present at all collections. As 
a general principle a first-time donor donates whole blood at least once before apheresis is 
considered; apheresis is not further discussed in this article.
Recording of donor complications and procedural problems
The occurrence of donor complications or procedural problems is recorded in eProgesa using 
codes. A new coding system was introduced in the first half of 2010 to improve its usefulness for 
analysis. Donor complications are classified into types that can be mapped to the International 
Society for Blood Transfusion surveillance classification based on clinical signs and symptoms14. 
Complications which involve outside medical care are also reported separately in the quality 
management database. The (obligatory) recording of complications and procedural problems 
is intended to capture all cases occurring on site. Donors are encouraged in written and verbal 
information at the first interview to inform the blood service about problems occurring off 
site. Also the standard questionnaire filled in by returning donors includes the question 
whether the previous collection went well and staff are instructed to retrospectively record 
any complications which are mentioned. 






We classified donor complications into broad categories: needle-related complications (painful 
arm, arterial puncture and haematoma), vasovagal reactions (pre-faints consisting of pallor, 
dizziness, sweating, nausea and/or vomiting as well as faints (loss of consciousness) with or 
without complications, injury or hospital admission); the phase of occurrence of a reaction 
was noted (during collection, afterwards in center or off site). We also examined the outcomes 
of procedural problems: failed stab (no blood flow following attempt to insert needle into 
vein for collection; repeat attempt in other arm is permitted if no blood entered tubing), flow 
problems (e.g. low flow or collection terminated because of exceeding maximum collection 
time of 15 minutes) or miscellaneous problems (e.g. machine failure). The term venepuncture-
related problem is used for the combined outcome of needle-related complication, failed stab 
and/or flow problems.
Statistical analyses
For all calculations the total number of (needle in) collections was used as the denominator. 
Rates of events per 1000 were calculated for first-time and for repeat donations separately. 
Multivariable logistic regression analysis to assess the associations of different variables was 
performed using IBM SPSS Statistics version 18 (IBM corporation, New York, USA). Associations 
are expressed by means of the odds ratio (OR) and 95% confidence interval (CI). Because of 
the low rate of the outcomes being studied, the odds ratio can be interpreted as a relative risk.
ReSuLTS
whole blood collections, recorded donor complications and procedural problems
A total of 551,744 whole blood collections were performed from 1st January 2010 to 31st 
December 2010; 28,786 (5.2%) came from first-time donors. Table 1 summarizes the key 
metrics of this cohort in comparison to the collections from repeat donors.
During the study period a total of 4,183 (0.76%) donor complications were recorded: 1,173 
(4.1%) in first-time donors and 3,010 (0.58%) in repeat donors. All rates were higher in first-
time donors. Table 2 shows data on vasovagal reactions: the rate for first-time donations 
was approximately nine times higher than for repeat donations, 3.6 and 0.39% respectively. 
Vasovagal reactions in first-time donors occurred during (as opposed to after) collection in 
74% of reacting female donors and 80% among males whereas a lower percentage of reactions 
presented during the collection of repeat donations (57% and 65% in reacting female and 
male donors respectively). The rate of vasovagal reactions with loss of consciousness (fainting) 
was 1.0% in female and 1.2% in male first-time donors, compared to 0.2% for female and 0.1% 




Table 1. Donor and donation characteristics of whole blood collections in 2010
First time Repeat Total
     N    %      N    %      N    %
overall 28786 522958 551744
Successful 27126 94% 514958 98% 541684 98%
Sex
Male 10059 35% 308662 59% 318721 58%
Female 18727 65% 214296 41% 233023 42%
Age (years)
Mean; median         32; 29      47; 49        46; 48
18-19 3827 13% 5587 1% 9414 2%
20-24 6907 24% 31747 6% 38654 7%
25-35 6994 24% 62927 12% 69921 13%
35-45 5116 18% 96607 18% 101723 18%
45-55 4078 14% 146895 28% 150973 27%
55-65 1850 6% 144064 28% 145914 26%
65-69 14 0% 35131 7% 35145 6%
Type of facility
Fixed 23258 81% 407288 78% 430546 78%
Mobile (setup or bus) 5528 19% 115670 22% 121198 22%
Among all the reported vasovagal reactions in the period July-December 2010 (the period 
after full implementation of the new codes which record the time of occurrence of a reaction), 
53 of the total number of vasovagal reactions in all donors commenced off site (3.3%), the 
majority in female donors (4.6% of vasovagal reactions in women) and five of the total in first-
time donors. In all, 34 complications required further medical care: 26 vasovagal reactions (six 
of these were delayed reactions after the donor had left the center and three were with injury; 
five of the total were in first-time donors), two donors with painful arm or nerve injury who in 
due course made a full recovery, five cases of local inflammation (phlebitis) and one donor who 
presented to hospital with a cardiac arrhythmia within 24 hours of donation.
Table 2 (pages 42-3) presents the analyses regarding associations between risk factors and 
vasovagal reactions. Female donors were less likely than men to experience a vasovagal 
reaction at their first donation except above the age of 45 years (overall OR 0.86, 95% CI 0.63-
0.98). At repeat donations, females were more likely to have a vasovagal reaction (OR 2.2, 95% 
CI 2.0-2.4). Younger donors had more vasovagal reactions than donors aged 35 years and older. 
The odds of vasovagal reactions were lower with greater body weight: OR 0.75, 95% CI 0.64-
0.88 for >70 kg vs ≤70 kg in first-time donors after adjustment for sex and age group. The odds 
for a vasovagal reaction showed a rising trend with increasing hemoglobin level in both male 






and female first-time donations, with or without adjustment for age group and other variables; 
this was also seen in repeat donations. Regarding blood pressure, analyzed only for above- and 
low-normal ranges vs normal values, in the group with the highest blood pressures there were 
marginally lower odds for vasovagal reactions. The time of day and maximum daily outdoor 
temperature had no clear association with the occurrence of vasovagal reactions in first-time 
or repeat donations. The data on type of collection facility showed lower odds for vasovagal 
reactions for mobile in comparison to fixed sites; however the mobile collections represent 
small numbers with combined data for setup sites and bus collections so the statistically 
significant lower odds ratio should not be over-interpreted. 
The overall rate of needle-related complications for first-time donations was 0.5% in female 
and 0.2% in male donors in comparison to 0.3% and 0.1% respectively for female and male 
repeat donations. Likewise the rates of flow problems and failed stab for first-time donations 
were approximately double compared to those for repeat donations and higher in female 
donors. Associations of donor sex, age and body weight with needle-related complications, 
flow problems and failed stab in the first-time group are presented in Table 3 (page 44). In 
addition to the increased rates in females, heavier donors were more likely to be affected by 
failed stab. There were no apparent associations of hemoglobin level or the variables of blood 
pressure level, type of center, temperature or time of day with needle-related complications 
(data not shown).
Donor return 
In the first-time cohort 130 female (0.7%) and 36 male (0.2%) donors were permanently 
deferred without subsequent donations because of complications or unsuitable veins. A total 
of 287 female and 65 male donors in the repeat donor cohort were permanently deferred for 
complications or venous access reasons, for rates of 0.1% and 0.02% per donation or 0.3% and 
0.1% per donor among female and male donors respectively. The return rate was 77% among 
female first-time donors and 81% among males; 85% and 91% among female and male repeat 
donors respectively. Among all donor attendances, return was associated positively with male 
sex (females OR 0.59; 0.58-0.60) and negatively with first-time donation (OR 0.67; 0.65-0.69), 
age groups 20-24, 25-34 and 35-44 (but not 18-19 years) in comparison to over 45 years. Table 4 
(page 45) summarizes the findings on return rate among first-time donors. If the first collection 
was successful despite a complication or problem during the collection or recovery period, a 
vasovagal reaction led to reduced donor return (return rate 61% in females and 67% in males) 
but there was no reduction from venepuncture-related problems. If the first donation was not 
successful, all types of problems were associated with lower donor return but the reduction 
was strongest for vasovagal reactions. The same effects were seen in repeat donors (repeat 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3. Rates of venepuncture-related problems at first whole blood donation (total N=28786)




































































































* Hematoma, arterial puncture, painful arm
† Failed stab: failed venepuncture, either leading to failure of collection or to successful collection after repeat 
venepuncture.
‡ Odds Ratio and 95% confidence interval, adjusted for sex and age group (categorical)
§ Collection <450mL (standard = 500mL excluding samples)
" Weight known for 21633 donations
Recurrence of complications at subsequent donation
In all 83% of female and 88% of male donors who experienced a vasovagal reaction at the 
first donation had an uncomplicated second donation (Table 5). For females the rate of 
vasovagal reactions at the second donation was 10.5% compared to 2.4% among donors who 
had smooth first donations, i.e. 4.4 times higher. In male donors the rate of recurrence was 
9.7% compared to 1.7% VVR in male donors who had a smooth first donation, i.e. 5.7 times 
higher. All these rates were higher than in the whole group of repeat donations (0.6 and 0.2% 
respectively, Table 2). Among the donors who made a second whole blood donation during 
the study period the occurrence of a vasovagal reaction on that occasion was associated with 
younger age (e.g. OR 1.7, 95% CI 1.3-2.4 for 18-19 year olds compared to donors older than 
34 years) and lower body weight (1.6, 95% CI 1.3-2.1 for weight <70 kg after adjustment for 
sex and age group). There was no sex difference for vasovagal reactions at second donation 
after adjustment for the other factors. In repeat donors who made a subsequent whole blood 
donation after a vasovagal reaction at the index donation the rate of recurrence of VVR was 6% 
in both male and female donors.






Table 4. Donor return within 1 year by first time donors depending on experience at first donation
experience at first 
donation
Females (all)
N per variable; return % 
Successful first donation
Return %; oR* (95% CI)
Incomplete first donation
Return %; oR* (95% CI)
No problem 17038 79% 79% 1.0 N=81, added to miscellaneous
Vasovagal 654 55% 61% 0.42 (0.34-0.53) 50% 0.24 (0.19-0.30)
Subgroup LOC† 98 47% 53% 0.36 (0.21-0.64) 41% 0.20 (0.11-0.36)
VP-related‡ 1014 62% 79% 1.0 (0.69-1.4) 58% 0.36 (0.31-0.42)
Miscellaneous 21 67% 75% 0.79 (0.21-2.9) 66% 0.26 (0.17-0.39)
Total 18727 77% 79% 1.0 55% Incomplete (all)¶
0.40 (0.32-0.49)
experience at first 
donation
males (all)
N per variable; return %
Successful first donation
Return %; oR* (95% CI)
Incomplete first donation
Return %#; oR* (95% CI)
No problem 9425 82% 83% 1.0 N=16, added to miscellaneous
Vasovagal 392 56% 67% 0.44 (0.32-0.59) 47% 0.19 (0.14-0.25)
Subgroup LOC† 60 45% 60% 0.38 (0.15-0.93) 43% 0.18 (0.10-0.34)
VP-related‡ 234 76% 85% 1.2 (0.54-2.7) 73% 0.59 (0.42-0.81)
Miscellaneous¶ 8 40% 33% 0.11 (0.01-1.3) 52% 0.23 (0.10-0.55)
Total 10059 81% 82% 1.0 59% Incomplete (all)**
0.39 (0.27-0.55)
* Odds Ratio and 95% confidence interval, adjusted for age (categorical)
† Loss of consciousness: data available for July-Dec 2010
‡ venepuncture-related: needle-related complication, failed stab or flow problems
¶ other complication or procedural problem
** Incomplete v. successful, adjusted for age (categorical) and type of complication
Table 5. First-time donors with subsequent whole blood donation during study period: how did it go? 
Female donors





No problem 13209 93.4% 2.4% 4.2% 0.1%
Vasovagal 351 82.6% 10.5% 6.3% 0.6%
VP-related* 641 83.5% 4.2% 12.3% 0
Miscellaneous 13 92.3% 0 0 7.7%
Total 14214 92.7% 2.7% 4.6% 0.1%
male donors





No problem 7752 96.2% 1.7% 2.1% 0.1%
Vasovagal 227 88.5% 9.7% 1.3% 0.4%
VP-related* 182 83.5% 3.8% 12.1% 0.5%
Miscellaneous 6 100% 0 0 0
Total 8167 95.7% 1.9% 2.3% 0.1%
* VP-related = venepuncture-related: needle-related complication, failed stab or flow problems
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Among the 4.4% of female and 2.2% of male donors who experienced needle-related 
complications (hematoma, painful arm or arterial puncture), flow problems or failed stab 
at first donation, 83% had second donations without problems; the rates of venepuncture-
related problems were 12% and 11% respectively in comparison to 2.7% and 1.2% respectively 
for female and male 2nd-time donations overall. Among the repeat donors the rate of recurrent 
venepuncture-related problems was 10% in female donors compared to 2.4% among female 
repeat donors overall; these figures were 5% vs.1.2% in male repeat donors. 
DISCuSSIoN
vasovagal reactions
In our cohort we found that female first-time donors had fewer vasovagal reactions than male 
donors, in contrast to the reverse in repeat donations. The more severe reactions with loss of 
consciousness were similar in first time male and female donors but showed a trend in the 
same direction. The associations with lower values for donor age, body weight and blood 
pressure in first-time donors were similar to those in repeat donors.
An increased risk of vasovagal reactions in male first-time donors has not previously been 
focused on, although collection center staff are generally well aware that men can faint at or 
even before their first donation8. Interestingly Eder et al found a rate of approximately 10% 
in females and 6% in males for vasovagal reactions recorded by the blood center in first-time 
18-19-year olds (in their study, which also included donors younger than 18, analyzing the 
effect of introducing deferral of young candidate donors with a calculated blood volume of 
less than 3.5 L)13, i.e. a rate which was higher in female than male donors in contrast to our 
study. The rate in donors of 20 years and older in the same organization was approximately 7% 
in female and 5% in male first-time donors5. Given the overall higher rate of reactions in these 
studies, it is possible that additional milder reactions occurred which were not captured by our 
reporting. In the study by Wiltbank et al., including donors from age 17, the rates of mild and 
moderate (but not severe) vasovagal reactions tended to be higher in male than in female first-
time donors in univariate analysis according to estimated blood volumes, but the differences 
were not statistically significant; rates were higher in females in other comparisons6. Most 
other studies do not analyze the role of sex as a risk factor separately in the first-time donor 
population7,8,12,15.
Hemoglobin level and vasovagal reactions
The rising trend of vasovagal reactions associated with the hemoglobin level in the first 
donation cohort after adjustment for sex and age was unexpected. Although the confidence 
intervals for the odds ratios at some hemoglobin levels cross unity, indicating not statistically 






significant, there is a consistent rising trend, robust to adjustment for the other included 
variables. A similar association was seen in the repeat donors. Preliminary findings of an 
association with hemoglobin level have been reported by other investigators (Bravo/Tomasulo, 
oral communication, Montreal April 201215). The observed trend may be due to unmeasured 
confounding factors. An explanation might be sought in smoking since smokers have higher 
hemoglobin levels. Recent studies at our blood center have surveyed donor characteristics 
(including smoking) and donors’ attitudes towards returning11,16. In a supplementary analysis 
of study data, no difference was found in the percentage of smokers between donors who 
reported having had a vasovagal reaction at their last attendance (Veldhuizen, personal 
communication, 2012). This makes smoking unlikely as an explanatory factor. Dehydration 
marginally increases the hemoglobin level and is also associated with vasovagal reactions17. 
Newman measured a hemoglobin drop of 0.13 g/dL following a 475 ml water drink so it is 
conceivable that the effect of hydration state on hemoglobin is large enough to contribute 
to the observed association18. Stress hemoconcentration is a third possible explanation of 
the association: a reduction of plasma volume and resultant increased hemoglobin level 
have been described in acutely stressed subjects19,20 while a contribution of stress in inducing 
vasovagal reactions is well recognized21-23. Further work is needed to examine the association 
with hemoglobin and possible further confounders.
Needle-related donor complications, flow problems and failed stab
Female donors were roughly twice as likely as males to be affected by needle-related 
complications, flow problems or failed stab. The overall higher rate of needle-related 
complications in first-time donors (both female and male) than in repeat donors is probably 
explained by selection. For some donors the first attempt at donation is a test of suitability of 
the venous access and some donors were subsequently deferred; others self-selected and did 
not return.
Donor return
Following a vasovagal reaction both male and female donors were less likely to return, the 
greatest reduction being seen in male donors whose first donation was unsuccessful. Reduced 
donor return following vasovagal reaction has been previously described9-11. Our results make 
it clear that the reduction is stronger following a vasovagal reaction in combination with an 
unsuccessful donation, a factor which was also noted by the REDS-II group24. It is possible that 
reactions during collection were more severe and that this led to poorer return. Another likely 
factor was suggested in the recent study by Veldhuizen et al which indicated that repeat male 
donors in particular report lower self-efficacy when (self-reported) reactions occur11.
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Donors with venepuncture-related problems at their first donation were also less likely 
to return, chiefly if the first donation was unsuccessful. The effect of experiencing a failed 
donation attempt in contrast to a successful donation with a complication (other than a VVR) 
does not appear to have been systematically examined, although the role of donor motivation 
and the psychological impact of donation complications has been highlighted10,11. Regarding 
needle-related complications Newman, reporting on a telephone survey in 2006, described 
an impact of bruises or sore arm which is less strong than vasovagal reactions but can have 
an additive effect with fatigue following blood donation to reduce return by 65%9. In a recent 
survey of lapsed donors in The Netherlands, fatigue was mentioned among physical reactions 
after donation which led to donors ceasing to donate25. Fatigue is not captured by a collection 
center-based study such as ours. 
Studies are consistent in reporting reduced return following donor reactions but the methods 
of measuring donor return vary: visits per year9, return within one year as in this study10,12, visits 
within 13 months26 or one year from eligibility27. The baseline rates reported by other authors 
are generally lower than in our study. For instance France et al reported return rates of 42% for 
first-time donors and 70% for repeat donors overall. Eder et al found a baseline return rate of 
35% following uncomplicated first donation; interestingly this group found – as was the case in 
our cohort – that donors below the age of 20 years had improved return rates in comparison to 
older donors with the exception of the top age band. In data from the REDS-II study the return 
rate for donors without reactions was 60-70% depending on the center24. 
Strengths and limitations
Our new coding system has made more detailed analysis of donor complications and of 
divers collection problems possible. However, a limitation of routinely recorded information 
is the likelihood of variable and under-reporting. Also the information has little detail and 
does not allow in-depth analysis of possible causes. In the course of the observation period 
an increasing tendency was observed in the recorded donation complications and collection 
problems. There was also a slight increasing tendency of the unsuccessful collections. A small 
number of serious complications (0.8% of the total) required outside medical care; these were 
not separately analyzed in this study, however they represent serious morbidity and should be 
addressed in future work.
As explained above, in the Netherlands all first-time donors have attended for interview and 
blood testing only prior to the day on which they make their first donation. In the Netherlands 
there is also a strong focus on donor management and high donor retention with only 
5.2% of whole blood donations coming from first-time donors. These aspects may affect 
generalizability since the occurrence of vasovagal reactions, needle-related complications and 






other problems at the first donation may have a greater impact in terms of lost subsequent 
donations in settings where a higher proportion of collected blood comes from walk-in and/or 
new donors. Differences in age distribution between our cohort and other countries will also 
reduce comparability of overall rates which should only be generalized to comparable donor 
populations; this has been partly addressed by presenting age-stratified analyses.
what does the study mean for practice?
Blood centers have the opportunity and challenge to move towards interventions to reduce 
donor complications, based on current knowledge of which donors are at risk. Our study 
shows that it is worth investing more effort in avoiding venepuncture-related problems at first 
as well as repeat blood donation. Also there is a need to regard male as well as female first-
time donors as “at risk” for vasovagal reactions. A number of interventions have been found 
effective in reducing the rate of vasovagal reactions, especially in first-time or inexperienced 
donors. Examples of such interventions are a 500 ml water drink shortly before donation, salt 
replacement, social distraction, instruction in applied muscle tension and the application of a 
lower collection volume for young donors with a small estimated blood volume13,18,21,22,28,29. The 
data on recurrence rates for complications provide insights which are relevant for both written 
and oral information provided to donors.
CoNCLuSIoN
In conclusion, our analysis of risk factors for vasovagal reactions at first-time whole blood 
donation, in contrast to repeat donation, showed that male donors were more likely to have 
a reaction than female donors, although more severe reactions with loss of consciousness 
revealed only a trend for higher incidence in males. Other risk factors had similar associations 
with vasovagal reactions among first-time and repeat donors. Female donors were at higher 
risk of needle-related complications at both first and repeat whole blood donations. Reduced 
donor return was seen following vasovagal reactions, as well as following venepuncture-
related problems leading to unsuccessful collection. Most donors (over 80%) who did come 
back after complications at their first donation had uncomplicated second donations.
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Relatives donating peripheral blood stem cells (PBSC) may be accepted for donation on less 
strict criteria than unrelated donors. We evaluated the occurrence of adverse events during 
procedure and follow-up, with a special focus on donors who would have been deferred as 
unrelated donors.
Study population and methods
All 268 related PBSC donors at our center (1996-2006) were included. Data were retrospectively 
collected from medical reports and standard follow-up. Health questionnaires were sent from 
2007. Medical outcomes of donors, deferrable or eligible according to international criteria for 
unrelated donation, were compared.
Results
Forty donors (15%) would have been deferred for unrelated donation. Short-term adverse events 
occurred in 2% of procedures. Questionnaires were returned by 162 (60%) donors on average 
7.5 years after donation, bringing total person years of follow-up to 1278 (177 in deferrable 
donors). Nine malignancies and 14 cardiovascular events were reported. The incidence rate 
of cardiovascular events in eligible donors was 6.5 (95% CI 2.5-12.3) per 1000 person years 
compared to 44.9 (95% CI 17.4-85.2) in deferrable donors; incidence rates of malignancies were 
4.6 (1.4-9.6) and 24.0 (6.0-53.9) per 1000 person years respectively in eligible and deferrable 
donors. All incidence rates were within the range of age and sex-matched general population. 
No auto-immune disorders were reported.
Conclusion
In both the eligible and deferrable related donors treated with G-CSF there are few short-
term and long-term problems. Occurrence of post-PBSC cardiovascular events and malignant 
disease in related donors appears to be within the range of the general population. 







Recombinant human granulocyte colony stimulating factor (G-CSF) is increasingly used to 
mobilize peripheral blood stem cells (PBSC) from healthy donors for allogeneic haematopoietic 
transplantation. In The Netherlands, PBSC collection has been performed in related donors 
since 1995. Counseling, collection and formal follow-up evaluations of unrelated donors 
conducted since 2004 are performed in accordance with national policies which conform to 
the World Marrow Donor Association standards.1 Although related donors are screened by 
independent physicians not involved in care of the patient, many of these donors are accepted 
for PBSC donation despite the presence of conditions for which they would be deferred if they 
were unrelated donors.
There is ample information about the short term effects of the PBSC procedure in related 
and unrelated donors, indicating an acceptable safety profile in comparison to bone marrow 
donation under general anaesthetic.2,3 Nevertheless, some serious and potentially life-
threatening complications have been described in allogeneic PBSC donation procedures, 
including splenic rupture,4,5 anaphylaxis, vasculitis and acute lung injury.6 Myocardial 
infarctions7, thrombo-embolic events, subarachnoid hemorrhage and cardiac arrests have 
been reported in at least thirteen cases either during G-CSF mobilization or within 30 days after 
PBSC harvest.8,9 Careful donor selection and observation might mitigate but not completely 
abolish these risks. 
Potential long-term complications are however less well known. There are some reports 
suggesting that administration of G-CSF may enhance malignant transformation in patients.10-12 
Some have reported the occurrence of hematologic and solid malignancies in healthy donors 
after donation of G-CSF mobilized PBSC. Furthermore, there are concerns about the potential 
development or exacerbation of auto-immune or systemic inflammatory diseases.3,8
These considerations regarding possible long-term effects have stimulated investigators to 
report on long-term follow-up of PBSC.13-15 However, long-term data concerning this topic in 
related donors is relatively scarce. Leitner et al. observed a cohort of 171 related donors.16 De 
la Rubia et al. described findings from a voluntary national registry of donation and follow-
up of predominantly related donors; Halter et al. reported international survey data from the 
European Group for Blood and Marrow Transplantation concerning both related and unrelated 
donors.17.8 None of these investigators found an increased incidence of malignancies; all authors 




Here we report follow-up data concerning a Dutch cohort of related donors. Because of the 
apparent difference in acceptance of related donors in comparison to unrelated donors, we 
also separately analyzed the data on the individuals who would not have been accepted under 
international screening criteria for unrelated donors. 
PATIeNTS AND meTHoDS 
Study population and PBSC procedure
The study cohort consisted of all related donors who underwent G-CSF mobilization and PBSC 
harvesting in Leiden University Medical Center from May 1996 to May 2006; the recipients 
were all patients at the hospital’s transplantation unit. The study was performed as part of a 
larger study which also comprised a prospectively enrolled group of donors and for which 
ethical approval was obtained from the hospital medical ethics committee.
Donor consent and medical clearance were performed by an independent physician. Subject 
to careful medical assessment, related donors could be accepted without upper age or body 
weight restrictions and sometimes in the presence of conditions which would constitute 
contra-indications for unrelated stem cell donation. A short description of the procedures and 
reference criteria is available as supplementary material with the online version of this article.
Donors received 10 µg/kg of G-CSF (FilgrastimR, Amgen Inc., Thousand Oaks, CA, USA) once daily. 
The white blood cell count was checked on the fourth morning in order for dose adjustment 
(halving) to take place if there was a rise above 70 x 10^9/L. The fifth dose was administered 
at the end of the fourth day. PBSC apheresis (Cobe Spectra, Caridian BCT, Lakewood, CO USA) 
was conducted on the fifth and, if necessary, sixth or subsequent day after an additional dose 
of G-CSF. If required, calcium was supplemented. Standard procedures allowed re-infusion 
of autologous platelets prepared from the stem cell product if there was a post-apheresis 
platelet count below 50 x 10^9/L or if it was below 80 x 10^8/L and a second day of apheresis 
was needed. After completion of the procedure, follow-up visits were scheduled at both one 
month and one year after collection.
Data collection
We extracted data from medical records and hospital information systems concerning 
predonation examination, donation and follow-up visits. Furthermore, we evaluated findings of 
medical screening and noted cases of acceptance where the donor would have been deferred 
under the criteria for unrelated donors. Mobilization and apheresis procedural data were 
extracted, including data on deviation from standard G-CSF schedule, use of a central venous 
catheter (CVC), the number of apheresis sessions, PBSC harvest, and reinfusion of autologous 






platelets prepared from the stem cell product. We retrieved information on requested target 
stem cell dose and yield, as well as on second requests for hematopoietic stem cells and donor 
lymphocyte collections (donor lymphocyte infusion, DLI). Finally, we recorded serious adverse 
events during follow-up.
In November 2007 we sent all donors a standardized health questionnaire by post. It comprised 
14 yes/no questions about medical diagnosis and treatment indicative of health problems 
since the donation; free text explanation was to be added if there were any “yes” responses. 
If the information given was not clear, one of the investigators (JW-O) contacted the donor 
by telephone or e-mail for clarification. When necessary medical details were requested from 
treating physicians with written consent from the donor. If the questionnaire was not returned, 
several attempts were made to check the address and find the donor. In January 2011 we 
accessed the hospital patient database to ascertain whether the recipient was alive or retrieve 
the date of death.
Definitions
Donor eligibility status was retrospectively assessed according to the Assessment Tool at 
workup from the National Marrow Donor Program (NMDP, 2009 version), Minneapolis, USA,18 
which were applied alongside general blood donation criteria. Broadly, unrelated donors must 
have no history of cardiovascular, diabetes, systemic auto-immune, eye or thyroid disease; 
donation is permitted up to age 60 years and a BMI of 40 kg/m2. Donors who would not have 
been eligible as unrelated donors are referred to as “deferrable donors”. 
All events requiring unscheduled medical examination or treatment from the start of 
mobilization until the one-month FU were taken into consideration and categorized as 
procedure related serious adverse events (SAE). 
Follow-up period is defined as the period starting one month after start of G-CSF to the latest 
contact with the donor. Contacts from 30 up to 100 days were considered as early follow-up 
and contacts from 100 to 730 days as late follow-up. 
The study outcomes were: 
1) Any malignancy (basal cell carcinoma excluded) 
2) Cardiovascular disease (CVD) after the procedure: a combined outcome of medically 
diagnosed fatal or nonfatal myocardial infarction, newly diagnosed coronary disease treated 
by medication or ischemic vascular disease, cardiac intervention or vascular intervention, 
cerebrovascular event, medically diagnosed transient ischemic attack for which treatment 
was instituted or venous thromboembolism




Data for all donors are presented, with comment on completeness of information. Means, 
medians and inter-quartile ranges (IQR) were calculated as descriptive statistics. For each 
donor, the number of follow-up years was determined from the time of donation to the latest 
contact date. Annual disease-specific incidence rates were calculated as the number of events 
per 1000 person years of follow-up, including all follow-up years until occurrence of the first 
event or until the latest contact date with donors without events. Confidence intervals are 
given for the 95% level of statistical significance. 
In order to compare incidence rates in our study group with those in the general population, 
age- and sex-specific incidence rates of cardiovascular disease and for cancer within the 
Dutch general population were retrieved from the national statistics database (www.statline.
cbs.nl/statweb) and from the national cancer registry (www.ikcnet.nl). Using the number of 
follow-up years for male and female donors in each age band we calculated the numbers of 
cardiovascular events and malignancies which would be expected in the study population if 
they had the same rate as in the general population. The standardized morbidity ratio (SMR) 
was determined, the ratio of observed events to the number expected. (A SMR less than 1 
means that there were fewer events in the study cohort than expected). The SMR and 95% 




The 268 related donors had a median age of 43 years (range 14-70) at donation; the demographic 
characteristics of the cohort are shown in Table 1. Forty donors would have been deferred 
according to NMDP criteria; the reasons are summarized in Table 2. Apart from age over 60 
years, body mass index (BMI) over 40 kg/m2 and hypertension (>160/95 mm Hg), medical 
contra-indications were present in ten donors: Factor V Leiden and/or previous deep venous 
thrombosis (n=2), coronary atherosclerosis and medication or revascularization (n=2; stable), 
aortic valve stenosis (stable), Parkinson’s disease, past treatment for breast cancer (more than 
5 years previously), diabetes mellitus type 1 or 2 (n=2), low concentration monoclonal (M) 
protein. 












Female (n; %) 115 (43%) 18 (45%)
Age at donation (years; median, IQR*) 42.8 (34.6-51.2) 60.4 (46.9-63.5)
BMI† (kg/m2; median, IQR*) 24 (22-28) 27 (24-30)
* Inter-quartile range
† Body mass index; known for 242 donors; 
Table 2. Deferral reasons of 40 deferrable donors* 
Deferral reasons
BMI (>40 kg/m2) 2
Hypertension (>160/90 mm Hg) 13
Other medical conditions 10
Age >60 years 21 
* More than one reason may apply
All procedural data were complete for 262 donors. Data on both target and yield of CD34+1 
cells were available for 234 donors. A collection of PBSC which was deemed adequate was 
achieved in all but three donors (1.1%; one female; two male donors deferrable for age over 
60 years). 
The collection was completed in one session in 176 donors: 66%; 76% for male and 52% for 
female donors. Most of the remaining donors underwent two days of aphaeresis; more than 
two sessions were needed in five (three males). A CVC was used in 22/268 (8%; 16 females). 
Four females out of these 22 donors were deferrable (two for hypertension, one for age >60 
years and one for both BMI >40 kg/m2 and hypertension). 
Follow-up visits are recorded for 230 donors (86%): 207 (77%) for early follow-up within 100 
days and 156 (58%) for late follow-up approximately a year after collection, some because 
of subsequent donations. There was no correlation between this follow-up attendance and 
survival of the recipient in the first six months after transplantation. One hundred and twenty-
two donors made subsequent donations: 113 donated lymphocytes (DLI) on one or more 
occasions, 7 donors underwent a second PBSC collection, one donor donated granulocytes 
and one donor donated bone marrow because of inadequate PBSC yield. The interval for 
subsequent donations was on average 329 days (inter-quartile range 170-398, median 248 
days). 




Procedure-related and short-term events
G-CSF led to changes in haematological parameters as expected. Eighty donors (30%) received 
autologous platelets (60 donors once and 20 donors twice or more) separated from the PBSC 
product. No transfusion reactions to platelets or serious biochemical changes were recorded. 
All of the mild elevations of LDH2 and bilirubin normalized within 6 weeks of harvest.
Table 3 shows the serious adverse events, one of which was related to the use of a CVC. In all, 
five donors (2%) required unscheduled medical attention and/or hospitalization during the 
period of G-CSF administration, harvest or during the direct follow-up period. We found no 
correlation between donor’s eligibility status and the occurrence of short term procedure-
related SAEs. The table also details two potentially serious dosing incidents.
A total of eight donors (3%) reported excessive tiredness in relation to the procedure which 
lasted for longer than a week, persisting until 6 weeks post donation in three cases. 






Excessive tiredness, 1 night hospitalization after PBSC M, 32 hypertension
Chest pain; no explanation F, 34 -
In-patient opiate pain control; G-CSF stopped day 3 with WBC 59.7 x 10^9/L M, 39 -
Inguinal venous thrombosis following CVC F, 45 -
Persistent pain symptoms at injection site F, 24 -
Potentially serious dose incidents 
Received incorrect G-CSF dose; no excessive rise in WBC 






Abbreviations: WBC = white blood cell count; DVT = deep venous thrombosis
Follow-up
Figure 1 summarizes the response to the follow-up questionnaire. Of the 268 donors, 162 
returned questionnaires giving a response rate of 60%. Responders were more likely to be 
female and older; there was no difference in proportion of responding donors according to 
death or survival of the recipient. 
The total number of donor follow-up years was 1278. The median follow-up was 4.5 years 
(range 0-13.6 years, IQR 0.6-8.4). No auto-immune disorders had been diagnosed during the 
follow-up period.
2 LDH = lactate dehydrogenase 
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Figure 1. Responses to the follow-up (FU) health questionnaire
Table 4 shows the reported long-term morbidity and follow-up outcomes together with the 
eligibility status of the donors. Fourteen (new) cardiovascular events had occurred and nine 
malignancies were diagnosed (excluding two donors who had been treated for basal cell 
carcinoma). In all, four donors are known to have died: one of a cardiovascular event, two 
from lung cancer while a fourth donor is known to have died but the cause is unknown. Four 
donors had a new diagnosis of type 2 diabetes and two, previously controlled on diet alone, 
had started taking oral antidiabetic agents; one of these six donors was in the deferrable group 
(for age >60 years). A donor who had suffered from persistent pain at the G-CSF injection site 
continued to be affected by fibromyalgia-like symptoms over five years after donation. The 
donor who had a femoral venous thrombosis still suffered from functional impairment in the 
leg and inability to work despite adequate anticoagulant treatment and resolution of the 
thrombus.
Table 5 (page 53) shows the incidence rates of cardiovascular events and of malignancies in 
the study cohort and age- and sex adjusted rates in the general population. The incidence 
rate of cardiovascular events in deferrable donors was 44.9 per 1000 person years (95% CI 
17.4-85.2) in comparison to 6.5 per 1000 person years (2.5-12.3) in eligible donors. The rates of 
cardiovascular events and malignancy in deferrable donors were in the range of the expected 
rates on the basis of age- and sex-specific rates in the general population; that of cardiovascular 
events in eligible donors was 0.6 times that of the general population (95% CI 0.2-1.1).
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Table 4. Follow-up findings in donors 
Sex (M/F),  
age (y) at donation
Interval (y) Problem during follow-up
Deferral reason  
(if present*)
F 45 and 24 - Persistent symptoms following procedure -
Cardiovascular total n=14; interval median 3.5y (range 6w-10.5y)
F, 70 5.8 Pacemaker implantation age
M, 37 3.2 Dissecting aneurysm; + -
M, 42 4.9 TIA -
M, 44 2.4 Myocardial infarction hypertension
M, 45 6.8 Myocardial infarction hypertension
M, 47 0.6 DVT -
M, 50 3.8 Peripheral vascular disease other
M, 52 3.7 Myocardial infarction -
M, 54 1.4 Angina pectoris diagnosed -
M, 55 4.9 Myocardial infarction hypertension
M, 57 1.5 Coronary revascularization -
M, 58 0.5 Vascular dementia -
M, 60 10.5 Cardioversion for atrial fibrillation age
M, 62 0.2 Myocardial infarction hypertension
malignancies total n=9; interval median 4.2y (range 3.0-10.1)
F, 16 4.1 Hodgkin lymphoma -
F, 46 4.2 Breast cancer -
F, 51 7.6 Bowel cancer -
F, 52 7.5 Lung cancer + -
F, 55 8.6 Breast carcinoma in situ -
F, 70 3.9 Breast cancer age
M, 44 10.1 Glioblastoma hypertension
M, 60 3.1 Rectal cancer age
M, 66 3.0 Lung cancer + age
+ Deceased; in addition a female donor in the eligible group, aged 56 at donation, is known to have died but the 
date and cause are unknown.
DISCuSSIoN
In this cohort of related donors, 15% would have not been accepted according to international 
criteria for unrelated PBSC donation. The likelihood of procedure-related serious adverse 
events was similar in these deferrable donors compared to donors who would have qualified 
as unrelated volunteer donors. The overall incidence of 2% short-term procedure-related 
serious adverse events associated with mobilization and PBSC harvest is consistent with figures 






previously reported in larger series. For instance the Center for International Blood and Marrow 
Transplant Research and European Group for Blood and Marrow Transplantation reported 15 
(1.1%) donation-related adverse events among 1337 allogeneic, mostly related PBSC donors, 
of which five were catheter-related.19
Table 5. Incidence rates (IR) of cardiovascular events and malignancies in study cohort and 
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*per 1000 person years
† expected rate per 1000 person years on the basis of age- and sex-specific population figures: “Hospital admission 
for disease of heart or circulation”
‡ SMR = standardised morbidity ratio
§ expected rate per 1000 person years: incident cancer diagnoses
The use of autologous platelet transfusions was implemented in our institution to comply 
with the guidelines, which do not allow stem cell apheresis if the pre-apheresis count is below 
80 x 10^9/L and which require daily monitoring until recovery of platelet counts if the post-
apheresis count is below 50 x 10^9/L. The procedure and its effect for the donor as well as for 
the stem cell product have been validated in our center. No adverse transfusion effects were 
observed.
In our long-term follow-up, the incidence rate of cardiovascular events in deferrable donors 
was 45 events per 1000 person years (95% CI 17-85) in comparison to 6.5 per 1000 person years 
in eligible donors. Rates of malignancy as well as cardiovascular events in both deferrable and 
eligible donors were in the range of age- and sex adjusted population rates. The point estimate 
of the standardized morbidity ratio for malignancy in the deferrable group was 2.4, however 
the 95% CI is very wide and our data cannot exclude an increased incidence up to 5.3 fold.
A theoretical concern has always been that use of G-CSF might favour the development of 
malignancy which would only become apparent after several years’ latency. The overall 
number of malignancies in our study was relatively high compared to other studies. Halter et 
al. reported the survey of both related and unrelated donors by the European Group for Blood 
and Marrow Transplantation which included almost 100,000 person years of follow-up of more 
than 23,000 PBSC donors. A total of 12 hematological malignancies occurred. While the rate 
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of hematological malignancy was higher in PBSC donors (1.2 versus 0.4 in 27,770 former bone 
marrow donors) this is probably explained by the higher age of related PBSC donors. Pulsipher 
et al. reported on follow-up findings ranging from 2 days to 99 months, median 49 months, on 
2408 unrelated donors (9% older than 50 years at donation) for recipients within the NMDP 
program; there were 21 non-hematologic malignancies excluding basal cell carcinoma, and one 
case of chronic lymphocytic leukemia. Concerning solid malignancies in former PBSC donors, 
Hölig et al. reported on 3928 unrelated donors in whom a total of 8 non-hematological and 
four hematological malignancies occurred. All investigators made comparisons with data for 
the general population and found no indication of any increase. Our cohort was approximately 
nine years older than the donors reported on by Hölig et al. who had a median age of 34 years; 
in our group only 2 malignancies occurred in donors aged below 40 at the time of donation. 
Although our data give no reason for concern that there might be a relevant increase in rate 
of malignancy, our cohort is small with a limited follow-up. More person years of follow-up 
would be needed to reject the possibility even of an implausibly high tenfold increase in rate 
of malignancies.20
The occurrence of auto-immune disease has less frequently been evaluated.16,21 So far, no 
investigators have found any indication of an increase of auto-immune conditions. Even if we 
consider a worsening of pre-existent type 2 diabetes mellitus as a possible effect of G-CSF, the 
six cases of new or worsened type 2 diabetes in our cohort are not in excess of what would be 
expected.
Our study benefits from the fact that it describes results from a single center using uniform 
standard procedures, however the relatively small group of donors remains a limitation. Its 
retrospective design, in particular the impossibility to trace a large number of donors, is a 
further limitation. This leads to missing data and a risk of ascertainment bias. The standardized 
morbidity ratio is calculated using age- and sex-specific population rates and the numbers 
of follow-up years in females and males in each five-year age band. Hence the result is fully 
adjusted for the fact that responders tended to be female and older. However any conclusions 
are based on the assumption that responders and nonresponders do not differ in their rate 
of the studied outcomes. In the observational setting the validity of this assumption cannot 
be tested. The difficulty of follow-up of related donors beyond a year after G-CSF exposure 
is encountered by other investigators.22,23,16 In The Netherlands, the standard schedule ends 
after the one-year attendance because the recipient’s health insurance only reimburses such 
follow-up to one year after donation. In our study this lack of routine follow-up was addressed 
by postal health questionnaires. However, nearly one-fifth of donors could not be traced and 
the overall response of 60% is suboptimal. 






A strength of the study is that it additionally captured data on cardiovascular disease (CVD) in 
the years following participation in the PBSC procedure. The incidence of late vascular events 
beyond 4 weeks has to our knowledge never been systematically recorded. The comparison 
with population data gives no indication of any excess morbidity. However, donors should 
normally constitute a lower-risk population, which is reflected in the incidence of CVD in the 
eligible group. Importantly, the incidence rate of approximately 45 per 1000 person years 
in the deferrable donors suggests that the safety margins in this group are smaller. Vascular 
disease is an important reason for deferring donors in view of the short-term risk of thrombotic 
complications. The Halter et al. survey describes clustering of cardiovascular events in the first 
weeks following the procedure. This was not seen in our study population although three 
cardiovascular events occurred in the 7 months following the procedure. 
Raised and/or drug-controlled blood pressure and age were the most frequent reasons for 
which the related donors would not have been eligible for unrelated donation. Candidate 
related donors, most of them being siblings of cancer patients, tend to be older than unrelated 
donors and age in itself brings increased risks of cardiovascular disease. In our center the donor 
assessment is performed by a physician who is not involved with the treatment of the patient. 
While this prevents any conflict of loyalties and minimizes risk, it is not a strict policy to rigidly 
defer all donors with one or more characteristics, including age, which would have led to 
deferral of an unrelated donor. Our data are consistent with other observations and show that 
if screening is performed as for unrelated donation, a population at lower (cardiovascular) risk 
will be selected. We also found that related donors who do not meet acceptance criteria for 
unrelated donors have a higher incidence of cardiovascular events, indicating smaller safety 
margins. Therefore, these criteria – including age – should in our opinion also be taken into 
consideration in the assessment of related donors. If a family member presents factors which 
would lead to deferral for unrelated donation because of potential higher risk of the procedure, 
it should not be assumed these risks may be accepted even if the donor is willing to proceed 
for the sake of a family member. 
Overall our results show acceptable risks of the use of G-CSF in these related donors concerning 
most important side effects. The long-term occurrence of cardiovascular disease and of 
malignancy for both eligible and deferrable donors falls within the range reported for the 
population. However, the small size of the study means that the confidence intervals are wide. 
There is insufficient information to conclude that there are no relevant long-term increases of 
cardiovascular or malignant disease. Late medical events will not be systematically captured 
unless active follow-up extends beyond the first year, not only for unrelated but also for related 
donors. We therefore strongly support efforts by the international transplantation community 
to ensure long-term follow-up for unrelated donors and related donors as well.22,23
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In conclusion, this study gives no indication of long-term increased risks of cardiovascular 
disease or of malignancies in related donors who have undergone G-CSF mobilization and 
PBSC apheresis, but cannot exclude this either because of the small size of the cohort. 
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Additional material published online only
Related donor selection procedures at Leiden university medical Center, 1996-2006
Related donor medical clearance G-CSF mobilisation and harvesting in the period 1996-2006 
was performed by a physician who was not involved in the treatment of the recipient. This was 
based on a general medical history, standard hematological and biochemical laboratory tests 
as well as standard infectious disease marker testing. In addition, bone marrow morphology, 
ECG, chest X-ray and monoclonal protein analysis were routinely performed.
Concerning the reference criteria, the center used guidelines which were initially based on 
national blood donation criteria supplemented by tools from the National Marrow Donor 
Program (NMDP, Minneapolis, USA). In 2004 national guidelines were implemented for 
unrelated donors as laid down by the national blood service, Sanquin Blood Supply. Of interest, 
the Dutch unrelated donor criteria are stricter than the NMDP and also stipulate deferral of 
donors on antihypertensive medication.
In principle these guidelines were used with the following routine deviations regarding donor 
safety: 
· No limit to donor age providing the donor is > 18 years
· No limit to donor weight 
· Blood pressure limits 160/100; use of antihypertensive drugs allowed
· Diabetes type 2 allowed if there was no apparent vasculopathy. 
In cases of incidental deviations (e.g. previous cardiac stent, bronchial asthma) a consultation 
of specialists was requested and the conclusions documented.
With respect to patient safety the applicable (national) blood donation guidelines were 
followed. In cases of deviation from these guidelines, with consent of the transplant centre 
donors with risk behaviour (chiefly travel risks, body piercing, homosexuality) could be 
accepted providing mandatory and any necessary additional tests (e.g. malarial antibodies) 
were negative. In cases of reduced safety for the recipient, the independent physician could 
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Development of new red blood cell (RBC) alloantibodies (alloimmunization) is one of the most 
frequent adverse reactions after an RBC transfusion. Few studies have investigated clinical risk 
factors for alloimmunization.
Study design and methods 
In this case-control study, the characteristics of all patients in whom alloimmunization occurred 
for the first time after an RBC transfusion in two hospitals between January 1, 2003, and May 
5, 2005, were examined and compared to a randomly selected control group who received 
RBC transfusions in the same hospitals during the same period without alloimmunization. 
Odds ratios (ORs) for the association between these characteristics and alloimmunization were 
calculated and analyzed with a logistic regression model.
Results 
Eighty-seven cases were found, and 101 controls were selected. Female sex (OR, 1.89; 95% 
confidence interval [CI], 1.05-3.38), diabetes mellitus (OR, 2.15; 95% CI, 0.91-5.05), solid 
malignancy (OR, 2.07; 95% CI, 1.00-4.30), and previous allogeneic hematopoietic peripheral 
blood progenitor cell (PBPC) transplantation (OR, 2.24; 95% CI, 0.64-7.81) were associated most 
strongly with alloimmunization, whereas lymphoproliferative disorders (OR, 0.33; 95% CI, 0.13-
0.81) and symptomatic atherosclerosis (OR, 0.52; 95% CI, 0.25-1.08) were associated with the 
absence of alloimmunization. All of these associations except for female sex became stronger 
after adjustment for possible confounders.
Conclusion 
Female sex, diabetes mellitus, solid malignancy, and previous allogeneic PBPC transplantation 
seem to be risk factors for alloimmunization, whereas lymphoproliferative disorders and 
symptomatic atherosclerosis seem to protect against it. Further studies are needed to confirm 
these associations and investigate underlying mechanisms.







Although blood transfusion is generally very safe, adverse reactions to blood transfusions 
remain an important clinical problem. Since 2002, transfusion reactions in The Netherlands 
have been reported to the TRIP (Transfusion Reactions in Patients) Dutch National 
Hemovigilance Office. TRIP captures not only severe transfusion reactions, like Serious Hazards 
of Transfusions (SHOT) in the United Kingdom, but also nonsevere transfusion reactions. In 
2004 and 2005, the most frequent adverse reaction reported to TRIP was the development 
of new red cell (RBC) antibodies (alloimmunization).1 Few studies have investigated clinical 
risk factors for alloimmunization, such as characteristics of the recipient, and previous findings 
have been inconsistent. Knowledge of clinical conditions that predispose to alloimmunization 
is important in two ways. First, it may influence the management of a patient. If a certain 
category of patients has a high risk of alloimmunization, the consequence could be more 
extensive antigen typing and matching. Second, more knowledge of associations between 
clinical conditions and alloimmunization may lead to a better understanding of the etiology of 
this transfusion reaction.
In this case-control study, we examined the case records of patients who developed alloim-
munization after a blood transfusion and compared them to patients who never developed 
such a reaction after a blood transfusion to identify risk factors for alloimmunization. As a sec-




We examined the case records of all patients in whom alloimmunization was reported in the 
Leiden University Medical Center and Haga Teaching Hospital in The Hague from January 
1, 2003, to May 5, 2005. We chose these two hospitals from the 82 hospitals that reported 
transfusion reactions to the TRIP organization in 2003 because they are large affiliated hospitals 
that cooperate on transfusion policy, and both are closely associated with the TRIP foundation. 
Alloimmunization was defined as the finding of a new antibody against RBC antigens other 
than Rhesus D and the ABO system. Only first-ever alloimmunizations were taken into account. 
We were looking for alloimmunization as a result of transfusion, not childbirth, so the patient 
must have had at least one earlier RBC transfusion to which the alloimmunization could be 
ascribed. Alloimmunization was ascribed to the last RBC transfusion given before the finding 
of the new alloantibody. All in-hospital patient records concerning the period around the time 
of the transfusion event were checked and analyzed by two of us (MB and JW).
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The control group for the alloimmunization cases was created by randomly selecting a RBC 
transfusion administered to a patient in the same hospital on the day after the alloimmunization 
was reported. Control patients had to fulfill the same criteria as case patients except for 
the fact that they did not develop an alloantibody. Therefore, the selected RBC transfusion 
should have been preceded by at least one “type-and-screen” procedure during which no 
new alloantibody was found. Furthermore, the patient should have received at least one RBC 
transfusion previously. If a control patient did not meet these criteria, another RBC transfusion 
was randomly selected from the following day’s list. A flow chart of the study design is shown 
in Fig. 1.
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Figure 1. Flow chart of study design
Patient characteristics
Demographic patient characteristics that we recorded were sex, age, and a non-European 
surname, as a measure of a potential genetic background difference from the main blood donor 
population, which is known to consist predominantly of non-immigrants in The Netherlands. 
The clinical characteristics we studied were the indication for the blood transfusion, the reason 
for the hospital admission during which the blood transfusion took place, previous transfusion 
reactions, the number of previous transfusions given in the same hospital (including the 
transfusion to which the reaction was ascribed; only RBC transfusions were counted), the 






number of children in the case of women, a history of autoimmunity (defined as any disease in 
which autoantibodies play a clear etiologic role or any disease of unknown etiology associated 
with autoantibodies [see Table 1 for list of conditions]), systemic inflammatory diseases without 
a clear association with autoantibodies, myelogenous marrow disorders (myelodysplasia, 
myeloproliferative disorders and myelogenous leukemia), lymphoproliferative diseases, a 
history of an allogeneic hematopoietic peripheral blood progenitor cell (PBPC) transplantation, 
a history of a solid organ transplantation, chemotherapy before the transfusion, and allergies.
Table 1. List of diseases defined as autoimmune
Graves’ disease
Hashimoto’s thyroiditis

































Abbreviations: ADAMTS13 = circulating protease of the ADAMTS family; ANCA = anti-neutrophil cytoplasmic 
antibodies; Anti-Hu = antibody directed against neuronal Hu antigen
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These are all conditions that could have a plausible relationship with a patient’s immune 
status. Other major disease categories apart from immune disorders that we investigated were 
a solid malignancy, diabetes mellitus, renal failure (defined as a repeatedly measured serum 
creatinine concentration of more than 150 mmol/L for at least 1 week; this cutoff level was 
chosen because it is elevated even for muscular young men and newborns), liver cirrhosis, and 
symptomatic atherosclerosis. All conditions were only taken into account if they were present 
at the time of the transfusion. Finally, we examined whether the patient had died since his 
blood transfusion. 
Blood products
We examined the following characteristics of the blood product to which the transfusion 
reaction was ascribed: leukoreduction, washing, subtyping (for C, c, E, e, Kell, Duffy (a), Duffy (b), 
Kidd (a), Kidd (b), M, N, S, and P1 antigens in addition to ABO and Rhesus D) and/or irradiation.
Analysis
For categorical variables, we calculated Mantel-Haenszel common odds ratio (OR) estimates 
for the correlation between transfusion reactions and patient characteristics with computer 
software (SPSS 11.0 for Windows, SPSS, Inc., Chicago, IL). We calculated adjusted ORs with a 
logistic regression model with the same program. We compared continuous variables with a 
t test.
ReSuLTS
We identified 70 cases of alloimmunization in the Leiden University Medical Center and 31 
in Haga Teaching Hospital. Aiming for an equal number of control patients, we selected 101 
control patients in both hospitals according to the method described above. Patients who 
had an earlier alloimmunization episode were excluded from the case group, so that 67 cases 
from the Leiden University Medical Center and 20 from Haga Teaching Hospital remained. 
Information on patient and clinical characteristics was obtained from hospital computer files 
or patient charts. Information on previous childbirths and allergies could not be obtained for 
all patients. ORs for the association between patient characteristics and alloimmunization are 
listed in Table 2. A solid malignancy, female sex, and diabetes mellitus seemed risk factors for 
alloimmunization. A previous allogeneic PBPC transplantation might be a comparable risk 
factor, although the confidence interval of the OR was wide. Lymphoproliferative disorders and 
to a lesser extent symptomatic atherosclerosis seemed to protect against alloimmunization. 
Thirty-six patients in the control group had died since their transfusion versus 23 in the case 
group; this difference is not significant. 






Table 2. Mantel-Haenszel adjusted odds ratios (95% confidence intervals) for association between 
patient characteristics and alloimmunization, stratified  by hospital.
Patient characteristic
Nr in case group 
(87)
Nr in control 
group (101)
odds ratio (95% CI)
Demographics
Female sex 51 44 1.89 (1.05 to 3.38)
Non-European surname 9 12 0.88 (0.35 to 2.20)
Previous childbirth 25 (n=32)* 21 (n=23)* 0.34 (0.06 to 1.82)
Transfusion history
Previous transfusion reaction other
  than alloimmunization
7 4 1.96 (0.56 to 6.93)
Number of previous transfusions over 
  12.5
28 35 0.83 (0.45 to 1.55)
Immunologically mediated diseases
Autoimmune disease 13 11 1.38 (0.59 to 3.23)
Other systemic inflammatory non-
  infectious diseases
7 10 0.76 (0.28 to 2.11)
Allergies 14 (n=79)* 18 (n=95)* 0.92 (0.42 to 1.98)
Haematological disorders
Aplastic anaemia 3 1 3.23 (0.33 to 31.89)
Myelodysplasia, myeloproliferative
  disorders, myelogenous leukaemia
10 14 0.85 (0.35 to 2.02)
Acute myelogenous leukaemia 5 10 0.54 (0.18 to 1.64)
Myelodysplasia 2 2 1.40 (0.20 to 9.80)
Lymphoproliferative disorders 7 22 0.33 (0.13 to 0.81)
Previous allogeneic haematopoietic
  stem cell transplantation
8 4 2.24 (0.64 to 7.81)
other
Solid malignancy 23 15 2.07 (1.00 to 4.30)
Chemotherapy within one month prior
  to alloimmunization
18 24 0.84 (0.42 to 1.67)
Chemotherapy within six months prior
  to alloimmunization
15 (n=67)* 23 (n=70)* 0.59 (0.28 to 1.26)
Previous solid organ transplantation 3 3 1.05 (0.20 to 5.38)
Renal failure 10 13 0.86 (0.35 to 2.08)
Liver cirrhosis 2 2 1.16 (0.15 to 8.81)
Symptomatic atherosclerosis 14 28 0.52 (0.25 to 1.08)
Diabetes mellitus 16 10 2.15 (0.91 to 5.05)
Descriptive statistics for the continuous variables in the case group and the corresponding 
control group are shown in Table 3. The patients in the control group had received slightly more 
RBC transfusions than those in the case group, although the difference was not significant. 
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The means of the age and the number of childbirths for the case and control group were not 
significantly different either. 
Table 3. Means and 5th and 95th percentiles (p5 and p95) for continuous variables for the 
alloimmunization cases and corresponding controls
median p5 p95
Age (years) Cases 56.5 12.8 84.2
Controls 56.0 8.1 84.3
Nr of previous red blood cell transfusions Cases 6.0 1.0 40.0
Controls 9.0 1.1 65.2
Number of childbirths* Cases 2.0 0.0 4.0
Controls 2.0 0.0 4.0
* women for whom information on childbirths was available
To correct the ORs for potential confounders, we performed logistic regression analysis. Given 
the relatively small numbers of cases, we only entered three or four variables together in a single 
model. We selected confounders that have an obvious relationship with certain risk factors. 
For example, allogeneic PBPC transplantation is usually used to treat lymphoproliferative or 
myelogenous marrow disorders and is obviously associated with previous chemotherapy. The 
results are listed in Table 4. 
Table 4. Crude and adjusted odds ratios (OR; 95% confidence intervals) for association between 
patient characteristics and alloimmunization
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The associations between alloimmunization and solid malignancy and diabetes mellitus be-
came stronger after correction. Female sex was slightly less strongly associated with alloim-
munization after correction. Strikingly, previous allogeneic PBPC transplantation seemed a 
much stronger risk factor after correction for lymphoproliferative disorders, myelogenous mar-
row disorders, and previous chemotherapy. The protective effects of lymphoproliferative disor-
ders and atherosclerosis seemed stronger after correction. The number of patients with female 
sex was not significantly different between patients with and without a lymphoproliferative 
disease. There were slightly more women among the patients with a solid malignancy than 
without a malignancy, but regression analysis did not influence the ORs much. The number of 
previous RBC transfusions was not a confounder.
DISCuSSIoN
In this exploratory study, we found a number of associations between patient characteristics 
and alloimmunization. Our data suggest that solid malignancy, previous allogeneic PBPC 
transplantation, diabetes mellitus, and female sex are risk factors for alloimmunization against 
RBC antigens, whereas lymphoproliferative disorders and symptomatic atherosclerosis protect 
against it. All these associations except for female sex were stronger after correction for 
possible confounders.
The main weakness of this study is the relatively small number of patients, which limits the 
power to detect small differences. This project, however, has demonstrated the usefulness of 
identifying side effects in databases like TRIP’s for etiologic studies and future studies can be 
undertaken with a larger number of participating hospitals.
The way in which the control patients were selected resulted in an overrepresentation of 
patients who had received many RBC transfusions. For that reason, the number of previous 
transfusions could not be evaluated as a risk factor. This ensures, however, that controls had 
enough exposure to develop antibodies. Certain RBC antibodies become undetectable within 
months after their development.2 Therefore, alloantibodies that have developed may be missed 
if a type and screen procedure is performed a long time after the RBC transfusion that caused 
their development. Owing to the fact that control patients received more RBC transfusions, the 
transfusion intervals in the control group, that is, the intervals between the last RBC transfusion 
and the transfusion for which a new type-and-screen procedure was performed, were usually 
shorter than the transfusion intervals in the case group, so that short-lived antibodies had a 
larger chance to be detected in the control group than in the case group. Therefore, differences 




In contrast, it is possible that patients with slowly forming alloantibodies are still in the control 
group because their antibodies are not yet apparent. If the risk factors for slow-forming 
alloantibodies are the same as those for early alloantibodies, this means that any associations 
found between alloimmunization and possible risk factors would be weakened because cases 
with an excess of risk factors are hidden in the control group. Therefore, if an association is 
found, it can only be stronger than suggested by the present data, a phenomenon called 
nondifferential misclassification. Furthermore, we judge the chances of slowly forming 
antibodies being missed in the control group to be small due to the large number of transfusions 
the control group received and the inherently high frequency of screening for alloantibodies.
The case-control design is a powerful tool for the detection of several risk factors at the same 
time. This design has rarely been applied in studies investigating risk factors for transfusion 
reactions.
Part of our findings are consistent with earlier studies. Female sex has been indicated as a 
risk factor.3-6 This is biologically plausible, because women are exposed to alloantigens during 
pregnancy and childbirth. Earlier studies suggested that chronic lymphocytic leukemia, 
a lymphoproliferative disorder, protects against alloimmunization.3,7 Our study found 
lymphoproliferative disorders as a group to be protective. This is also biologically plausible, 
because the malignant clone may displace functional T and B cells. Moreover, most of the 
patients with lymphoproliferative disorders receive intensive chemotherapy, which suppresses 
immunity. A protective effect of intensive chemotherapy has been suggested in an earlier 
study.8 Our study suggests a slightly protective effect of chemotherapy. Aplastic anemia has 
been suggested to be a risk factor.3 Our data are consistent with this, although the numbers 
are very small.
Some of our findings are inconsistent with earlier studies. In a number of studies, 
alloimmunization seemed to be associated mainly with racial differences between donor 
and recipient populations and the number of previous blood transfusions.10-13 We found no 
indications for this with our rather crude method of comparing surnames. Furthermore, an 
association between alloimmunization and autoimmune diseases has been reported,14 which 
we did not find either. One study found liver cirrhosis and myelodysplastic syndromes to be 
risk factors,3 which we could not confirm, possibly due to the very low frequency of these 
conditions in our study population. Finally, splenectomy was found to be a risk factor in one 
study.12 In our study population, only one control patient had had a splenectomy.
Finally, we found associations that have not been reported earlier. A new finding is the 
increased risk of alloimmunization in patients with solid malignancy, in spite of the fact that 






many of them were receiving chemotherapy. A possible mechanism for this is a state of 
increased immune activation. A recent animal model suggests that alloantibodies are formed 
more easily in the context of an inflammatory state.15 Another finding that has not been 
published earlier to our knowledge is the increased risk of alloimmunization after an allogeneic 
PBPC transplantation. There are several reports on hemolysis due to alloantibodies after an 
allogeneic PBPC transplantation, however. The development of these antibodies might have 
a relationship with major and minor incompatibility between donor and recipient and the 
persistence of mixed chimerism. This might play a direct role because part of the recipient’s 
immune system might recognize the transfused antigens as foreign, or an indirect, role —
again in the context of an inflammatory state. Also, a passenger lymphocyte mechanism has 
been implicated.9 Surprisingly, we found diabetes mellitus to be a risk factor. For this finding 
we have no pathogenetic explanation. We also found symptomatic atherosclerosis to protect 
against alloimmunization, although we have no theory for a possible underlying biologic 
mechanism. Obviously, we do not know whether these findings are the result of an unknown 
pathophysiologic mechanism or the association is caused by random variation in the small 
numbers. 
In conclusion, female sex, diabetes mellitus, solid malignancy, and previous allogeneic PBPC 
transplantation seem to be risk factors for alloimmunization against RBC antigens, whereas 
lymphoproliferative disorders and symptomatic atherosclerosis seem to protect against 
it. Further studies are needed to confirm these associations and investigate their possible 
underlying mechanisms. For this goal, databases such as TRIP can be very useful.
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Male-only fresh-frozen plasma for transfusion-
related acute lung injury prevention: 














TRALI is one of the most serious complications of blood transfusion. It can be caused by 
incompatible leukocyte antibodies in transfused plasma. The objective of this study was to 
quantify the reduction of TRALI following introduction of male-only plasma for transfusion as 
a preventive measure, which took effect in 2007.
Study design and methods
In The Netherlands all cases of TRALI are reported to the national hemovigilance office. All 
reported cases of TRALI from 2002 to November 2009 were considered for inclusion. Those 
meeting the Canadian consensus clinical definition were included and subdivided according 
to whether or not the patient had received quarantine FFP (Q-FFP) in the six-hour period before 
the reaction. The numbers of TRALI cases involving plasma donated before the measure and of 
those involving plasma donated after the measure were compared to TRALI cases that did not 
involve Q-FFP in order to adjust for reporting bias.
Results 
110 cases were included in the analysis. Of 68 cases before the measure, 36 involved Q-FFP. 31 
cases occurred after the measure of which 8 involved Q-FFP. Eleven occurred in the transitional 
period, of which 4 involved Q-FFP. The population attributable risk of pre-measure plasma 
among TRALI cases occurring before the measure was 0.33 (95% CI 0.09 to 0.51).
Conclusion 
In The Netherlands the male-only Q-FFP measure was associated with a 33 percent reduction 
of TRALI cases.







Transfusion-related acute lung injury (TRALI) is one of the most serious transfusion reactions and 
one of the top three causes of transfusion-related mortality in most hemovigilance registries.1,2 
According to the Canadian consensus criteria, respiratory distress, hypoxia, increased airway 
resistance and frothy sputum in ventilated patients arise within six hours of transfusion and 
are associated with (new) infiltrates showing on X-ray. This is assumed to be due to neutrophils 
entering the pulmonary interstitium and fluid loss into the alveoli.3,4 TRALI has been attributed 
to incompatibility between donor leukocyte antibodies (HLA class I and II antibodies as well as 
anti-granulocyte antibodies) in transfused plasma and recipient leukocytes.5,6 However, in many 
cases no leukocyte incompatibility is found. In the postulated two-hit mechanism of TRALI, a 
first hit consists of neutrophil priming or initial triggering of endothelium in the pulmonary 
vascular bed. The second hit can be the transfusion of leukocyte antibodies incompatible with 
the recipient or other factors that arise during storage of blood products.4
The proportion of TRALI cases which are deemed to be caused by leukocyte incompatibility 
has been estimated at up to 89%.3 Leukocyte antibodies are mainly induced by pregnancy 
or blood transfusion.7 Therefore several countries where fresh frozen plasma (FFP) is used for 
transfusion have introduced FFP preferentially or exclusively derived from male donors who 
have never received a blood transfusion with the aim to reduce the number of TRALI cases. In 
the UK, analysis of ten years of TRALI registration within “SHOT” (Serious Hazards of Transfusion) 
the national hemovigilance office shows that implementation of preferential male-only FFP 
has led to a near-disappearance of TRALI associated with leukocyte incompatibility following 
plasma transfusion.2 However this may be partly a consequence of the SHOT method of 
assessing “imputability”, the likelihood that the clinical picture of TRALI is related to transfusion. 
SHOT grades imputability of TRALI reports higher in the presence of patient-incompatible 
leukocyte antibodies. The international consensus definition for TRALI does not include 
leukocyte incompatibility as a criterion.8,9
The male-only measure became effective in The Netherlands for all quarantine plasma (Q-FFP; 
henceforth in this article we will refer simply to “plasma”) distributed to hospitals since 1st July 
2007. The aim of the present study was to quantify the reduction of TRALI cases, as defined by 
the international consensus definition, following implementation of male-only plasma.
meTHoDS 
Design and study setting
We performed a cohort study among all patients who had a diagnosis of TRALI in The 
Netherlands from 2002 to 2009 with the aim of comparing the incidence of TRALI before and 
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after the male-only plasma measure became effective. In The Netherlands all suspected cases 
of TRALI are reported to TRIP (Transfusion Reactions in Patients), the national hemovigilance 
system which became fully operational in 2003. The reports are submitted on a paper or digital 
reporting form; additional information is requested from hospitals if necessary for standardized 
classification. TRIP also receives information on reported TRALI cases from the blood service. 
Inclusion was terminated on 15th November 2009, when a further measure was introduced in 
the production of platelet concentrates.
Patients
TRALI case definition
TRALI cases had to conform to the criteria of the international consensus definition of TRALI: 
a patient was included in the cohort if there were clinical findings of hypoxia with bilateral 
infiltrates on the chest X-ray, starting within 6 hours of the transfusion of a labile blood 
component; circulatory overload had to be excluded as a (more likely) cause. 8,9 Information on 
the clinical condition of the patient was evaluated for known risk factors for acute lung injury 
or other possible causes of hypoxia with a temporal relationship to the respiratory distress.
All reports were reviewed by a panel of transfusion experts and assessed on clinical information 
without considering results of leukocyte serological investigation, which in most cases were 
not available to the reviewing committee. If the patient had a risk factor for acute lung injury 
(e.g. aspiration, toxic inhalation, lung contusion, near-drowning, cardiopulmonary bypass, 
pneumonia, acute pancreatitis, sepsis) the case was flagged as a “possible TRALI” according to 
the consensus definition.8,9 Cases were excluded if there were other more likely causes for the 
respiratory problems. All blood components received by the patient up to 6 hours before onset 
of respiratory symptoms were recorded.
Transfusional setting and analysis periods
In The Netherlands plasma for transfusion is prepared from apheresis plasma which is released 
after the donor has been retested for infectious diseases after a minimum of six months. From 
October 2006 all plasma collected for Q-FFP and from July 2007 onwards all plasma distributed 
to the hospitals was from male never-transfused donors. Units distributed before 1st July 2007 
were not recalled from the hospitals and were transfused from the hospital inventory over 
the following months. Cryosupernatant plasma is occasionally used for refractory TTP1 and 
prepared on demand from Q-FFP.
1  Thrombotic thrombocytopenic purpura






Since 1988 all platelet products and since 2002 all red cell components have been leukoreduced 
by prestorage filtration (<1x 10^6 leukocytes per unit). Plasma for transfusion meets the same 
specification. Red blood cell concentrates are stored in SAGM additive solution and contain 
less than 20 ml of residual donor plasma. Over 90% of platelet concentrates are prepared from 
five pooled buffy coats and resuspended in either 200 ml of plasma from one of the donors 
(approx. 70% of total platelet units) or platelet additive solution with residual circa 85-100 ml 
plasma consisting of <20 ml of plasma from each buffy coat. Apheresis platelets are collected 
in a volume of 150 to 400 ml donor plasma and are used for special indications such as HLA-
matched platelets, Parvo B19 or CMV-safe products2. During the study years the total number 
of blood components distributed to the hospitals annually was approximately 700,000 units. 
For TRALI cases reported after July 07 the donation date of transfused plasma was checked. 
Reports where any plasma had been transfused were classified according to the donation 
date of the plasma as occurring with products from before or after the measure. TRALI cases 
involving no plasma were assigned to the same period as any plasma-associated TRALI in 
that month. The three analysis periods were: before the measure (2002 – June 2007), the 
transitional period during which cases were associated with plasma both from before and after 
the measure (July – November 2007) and after the measure (December 2007 – 15 November 
2009). Plasma-associated cases during the transitional period were assigned according to the 
date of donation of the plasma and the cases without plasma were assigned half to before and 
half to after the male-only measure for purposes of calculation.
Statistical analysis
We compared the number of reported TRALI cases from before introduction of the male-only 
measure with the number after it had become effective. If the measure was effective a reduction 
will be seen in the number of TRALI patients who received one or more units of plasma, with 
or without other blood components, when only male plasma was available for transfusion. 
The number of reported cases where the patient had not been transfused with plasma reflects 
the overall sensitivity of TRALI detection and reporting in any period. This number was used to 
correct for changes in this sensitivity.
We expected that after the measure became effective there would be a drop in the proportion 
of TRALI reports after transfusion of plasma against the total number of reported TRALI cases. 
The drop represents the population attributable risk (PAR) for female plasma as available prior 
to the measure, and corresponds to the fraction of TRALI prevented by the implementation 
of male-only plasma. An additional sensitivity analysis was performed, calculating the PAR 
separately for the ramp-up phase of reporting to TRIP (2002–4) and for the plateau phase 
2  HLA=human leukocyten antigen; CMV = cytomegalovirus
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(from 2005 – mid 2007). The main result was recalculated with the omission of reports from the 
interim period as an additional verification.
The formula used is: 
PAR = (R – R0)/R = 1 – risk after/risk before
with R the risk of TRALI in transfusion recipients before the measure and R0 the risk in transfusion 
recipients after the measure.
During the reporting period there was little change in numbers of blood components 
distributed in The Netherlands,10 so stable proportions of patients transfused with different 
types and combinations of types of blood component are assumed. The number of TRALIs (N) 
reported in a given period is 
N = X * f * Y 
in which X is the “true” incidence rate of TRALIs (number per year), f is the proportion detected 
and reported and Y the follow-up period (years). 
PAR = 1 – (risk after/risk before) = 1 – XA/XB = 1 - (NA/(YA * fA))/(NB/(YB * fB))
For TRALIs where no plasma was transfused the “true” rate cannot have changed since the 
measure was introduced so 
XB, no plasma = XA, no plasma
Since we collected TRALIs with and without plasma concurrently we can also assume that f at 
any time is the same for TRALI with and without plasma. This allows the proportion YA * fA/(YB * 
fB) (for all cases) to be estimated by NA, no plasma/NB, no plasma. Thus the PAR was calculated as 
PAR = 1 – ((NA/NB) * (NB, no plasma/NA, no plasma)) 
simply using the observed numbers of reported TRALIs.
A confidence interval for the PAR was calculated using 
Var[ln(1-PAR)]=1/NB,no plasma-1/NB+1/NA, no plasma-1/NA.
11
ReSuLTS 
Characteristics of the study population
The study population comprised 110 patients with TRALI approved by expert review as 
complying with the TRALI definition. Figure 1 shows the numbers of all suspected TRALIs per 
year from 2002 to 2009 according to the types of blood component(s) received by the patient.
TRALI before and after the male-only plasma measure
The earliest TRALI involving one or more plasma units from after the measure occurred in July 
2007, the last case where one or more plasma units dated from before the measure occurred in 
November 2007. Thirty-one of the TRALI cases were designated as “possible TRALI” according 
to the consensus definition because one or more other risk factors for acute lung injury (ALI) 
were present.



































Plasma and other bc
RBC and plts
Figure 1. Reports of suspected TRALI and associated blood components, 2002-2009
bc = blood component(s)
outcomes and estimation
The annual number of reports of TRALI rose for all types of blood component between 2002 
and 2007, which can be attributed to increased awareness of TRALI. The initial rise in total 
annual number of reports to the new hemovigilance reporting system had levelled off in 
2005. A total of 68 cases of TRALI occurred before the male-only plasma measure of which 
36 involved plasma, with or without other types of blood components. From December 2007 
there were 31 cases of which 8 involved plasma. Four of the eleven cases in the transitional 
period were associated with plasma, two with plasma donated before the measure. Table 1 
summarizes the numbers of reports with and without plasma per analysis period. 
















1 – ((NA/NB) * (NB, no plasma /
NA, no plasma))
All TRALI 68 11 31 110 1-((36.5/73.5)*(35.5/26.5)) = 0.33
(95% CI 0.09-0.51)
with plasma 36 2 before
2 after
8 48
without plasma 32 7 23 62
TRALI, excluding cases 
of “possible TRALI”
48 8 23 79 1-((27/52)*(22.5/18.5)) = 0.37
(95% CI 0.06-0.58)
with plasma 28 2 before
1 after
7 38
without plasma 20 5 16 41
* If cases in the interim period are left out of the calculation the PAR becomes 1 – ((31/68)*(32/23)) = 0.37 (0.12-
0.54) and 0.40 (0.08-0.61) excluding “possible TRALI”.
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The overall PAR was 0.33 (95% CI 0.09-0.51) for all TRALI. After exclusion of “possible TRALI” 
it was 0.37 (0.06-0.58). In the sensitivity analysis comparing the separate periods of 2002–4 
and 2005 – mid 2007 to that after the measure the PAR was comparable though with a wider 
confidence interval: PAR 0.41 (95% CI –0.07 to 0.67); and 0.31 (–0.02 to 0.54) respectively. 
DISCuSSIoN 
The male-only plasma measure was associated with a 33 percent reduction of TRALI in The 
Netherlands, a reduction totally driven by lower numbers of cases where plasma had been 
transfused in combination with red blood cells and/or platelets. The finding implies that 
against the average number of approximately 20 reports per year before the measure, some 7 
of the previously reported cases annually may have been avoided by the measure. Moreover, 
since the plasma measure can only prevent TRALI caused by plasma, this size of effect means 
that the majority of TRALI cases where plasma had been transfused prior to the measure were 
in fact caused by female plasma. The figures in Table 1 show that TRALI cases where plasma had 
been transfused are in the majority in the period before the measure and that this is reversed 
after the measure. (See also supplementary figure 2 at the end of this article, not published.)
We observed a higher attributable risk when cases of “possible TRALI” were excluded. In some 
cases where other risk factors for ALI were present, ALI was probably not induced by the 
transfusion. Inclusion of some such cases leads to dilution and underestimation of the effect 
of the measure. The higher attributable risk after exclusion of “possible TRALI” is probably more 
valid and provides further support that there is a true reduction.
Strengths and limitations
The strength of this analysis lies in its inclusion of all reported patients meeting the standardized 
criteria for TRALI in a whole country, with as little as possible interference from awareness of the 
results of leukocyte serology testing. Reporting of such a serious complication as TRALI to TRIP 
and/or the blood service is expected to be nearly complete. An important advantage is that 
we use the number of TRALIs not associated with plasma to correct for variability in detection 
and reporting behavior. The fact that a similar effect is found in the sensitivity analyses of the 
sub-periods supports our use of these cases as a comparator.
A limitation of the study is its observational nature and reliance on spontaneous reporting of 
cases. A recent analysis has shown that bias may operate in the decision whether to report 
a reaction as suspected TRALI.12 If any interpretation bias operated it could be expected to 
favor reports of TRALI associated with FFP and to have most strongly influenced TRALIs where 
FFP was the sole product transfused. However the present findings do not support this. Also, 






since most clinicians in The Netherlands are not aware of the plasma measure this reporting 
preference is unlikely to have changed and therefore could not have biased our analyses.
The overall blood use and the proportions of type of blood component remained largely stable 
over the study period, except for a slight (less than 10%) drop in the number of both RBC and 
plasma units distributed to the hospitals between 2002 and 2004 (see Table 2). Thus a relative 
reduction of the use of plasma as compared to cellular blood components has not contributed 
to a lower incidence of TRALI. The assumption of unchanged risk associated with RBC and 
platelet transfusion could also be challenged if female plasma donors returned to whole blood 
donation. In fact however female donors continued to donate plasma for fractionation. 
Table 2. Annual blood use (to nearest 1000) and rate of reported TRALI
Blood components distributed (to nearest 1000 units) Total number of TRALI and overall 
rate per 100,000 units distributedYear RBC Plasma Platelets
2002 630 105 50 6 0.76
2003 617 112 48 7 0.90
2004 585 97 53 6 0.81
2005 568 92 51 13 1.83
2006 556 92 51 23 3.29
2007 555 93 54 26 3.71
2008 554 98 51 19 2.70
2009 564 90 49 12 1.70
The overall incidence of reported TRALI appears to show a downward trend after the year 
2007 (figure 1). Analyses by TRIP show that there have been increased reports of transfusion-
associated circulatory overload and other transfusion reactions, suggesting that the diagnosis 
of TRALI is assigned more critically.1 As explained above the calculated drop in TRALI is based 
on the ratio of TRALI cases where plasma was (one of blood components) transfused, to cases 
without plasma, and would be valid despite a reduced trend in the overall level of TRALI 
detection and reporting.
Consistency with prior findings
A reduction by 33% is slightly higher but in the same order of magnitude as suggested by 
the findings of leukocyte serology as reported recently from our country.13 The reduction is 
comparable to observational pre- and post intervention data on ALI in ruptured abdominal 
aneurysm repair from a single UK center (0.39, 95% CI 0.16-0.90).14 An American study of TRALI 
fatalities in 2003–5 found that 18 out of 38 probable TRALI fatalities (47%) were associated with 
female antibody-positive fresh frozen plasma and might be avoided by limiting transfusion 
of leukocyte antibody-containing FFP.15 This proportion is again similar although the relative 
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contribution of alloimmune-mediated TRALI associated with FFP would not necessarily be 
the same among cases with fatal outcome. A recent overview of probable TRALI (including 
nonfatal cases) reported by the American Red Cross describes a drop from 30 cases associated 
with plasma transfusion in 2006 to 10 cases in 2008 after implementation of male-predominant 
plasma for transfusion.16
In the United Kingdom reports to SHOT of TRALI associated with FFP containing patient-
incompatible leukocyte-reactive antibodies dropped from 10 in 2003 to none in 2004–7 since 
implementation of preferential use of male plasma. This suggests that, if supply of exclusively 
male plasma is achieved, this measure could prevent most or all TRALI caused by plasma. As 
explained above, SHOT assesses the likelihood that a suspected TRALI is indeed transfusion-
related partly on the basis of the finding of concordant HLA antibodies in the transfused unit(s). 
The overall rate of reported TRALI (assessed as highly likely, probable or possible) before the 
change in the UK was 1.9 per 100,000 units, compared with 2.6 per 100,000 in 2005-6 in our 
registry. In The Netherlands, the expert assessors were blinded to the results of this investigation 
from 2007 onwards. Prior to that year they were not consistently blind to the results but these 
were not used for the clinical definition of TRALI. The calculated reduction in The Netherlands is 
remarkably similar to the effect in the UK despite the important difference in the assessment of 
cases; this is in line with the hypothesis of TRALI cases having being prevented by elimination 
of patient exposure to incompatible leukocyte antibodies in plasma from female donors.
meaning of the study, implications for clinicians and policymakers
Not in all countries are donors excluded if they have been recipients of transfusion. Plasma from 
male donors who have (ever) been transfused should logically also be excluded, although it 
has been established that pregnancy-related HLA antibodies persist for longer than antibodies 
developed following blood transfusion. In The Netherlands it was possible to implement the 
measures for no significant costs and without serious threat to the blood (plasma) supply. We 
adopted the use of male-only plasma for the plasma added to platelet pools in mid November 
2009. A further safety improvement will be obtained if this achieves a comparable risk reduction 
for the platelet concentrates preserved in plasma.
Some blood services have implemented antibody screening for all female donors, with 
repetition of the screening following pregnancy.17 This should have comparable efficiency in 
preventing TRALI, while resulting in fewer donor deferrals, but is associated with increased 
costs. Other countries (e.g. France, Ireland, Norway, Finland) use pooled solvent-detergent (SD) 
virally inactivated plasma and report that TRALI is not seen in association with this product. 
Reduction in non-infectious transfusion complications (both TRALI and allergic reactions) 
was included as an important aspect in a recent review of cost-effectiveness aspects of this 
product.18







In conclusion, our findings suggest that in The Netherlands the male-only plasma measure has 
led to a reduction of TRALI cases of about 33 percent.
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Figure 2. (not published with article) Numbers of reported TRALI, excluding cases of “possible 
TRALI”, before and after the measure
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Background and objectives 
It has been suggested that the rate of reported transfusion reactions is positively correlated 
with safety of the transfusion chain in a hospital. We evaluated this assumption in the TRIP 
Dutch National Hemovigilance Office database taking reported incorrect blood component 
transfused as a proxy for unsafe transfusion.
methods 
Reports from 2006-2010 and annual numbers of transfused blood components from the 103 
hospitals were analysed. The rate of transfusion reactions per 1000 blood components was 
calculated per hospital. Logistic regression analysis was performed between reporting of at 
least one incorrect blood component and tertile of transfusion reaction rate.
Results 
Out of the 103 hospitals, 101 had complete data in some and 93 in all five years. In all, 72 had 
reported at least one incorrect blood component transfused; this was associated with blood 
use level and also with rate of reported transfusion reactions: odds ratio 4.2 (95% confidence 
interval 1.3-13.7) in the highest vs. the lowest tertile after adjustment for blood use level.
Conclusion 
Hospitals in The Netherlands which report more transfusion reactions per 1000 units are also 
more likely to have reported incorrect blood component transfused. The data do not support 
that hospitals with a higher rate of transfusion reaction reports are safer. 







Blood transfusion is an essential part of modern health care without which many advances in 
medical and surgical treatment would not have been possible. Nevertheless, there is always the 
risk of an adverse reaction or of patient harm resulting from an error or other type of incident. 
Since the high-profile blood scandals of the 1980s and 1990s, national haemovigilance systems 
have been put in place to receive, register and analyse reports of transfusion reactions and 
adverse incidents in the blood transfusion chain from donor to recipient.1-3 In the European 
Union, legislation requires member states to have a haemovigilance system to collate 
mandatory reports of serious adverse reactions and serious adverse events which may be 
associated with the quality or safety of blood or blood components for transfusion.4
The work of haemovigilance registries serves to document the occurrence of transfusion 
reactions as well as of errors and incidents in the transfusion chain. Haemovigilance 
systems highlight the risks associated with the transfusion of labile blood products, make 
recommendations for changes in practice and can trigger research. Some registries have 
presented evidence of decreases in reports of a particular type following interventions. Any 
decline in voluntary spontaneous reports must however be examined critically against other 
information, e.g. a different type of report which has remained static or increased.5,6 The SHOT 
(Serious Hazards of Transfusion, the UK haemovigilance system) 2009 annual report comments: 
“….. the hallmark of an effective vigilance system, in that the participation in the scheme, and 
thus total reports, increases as users become engaged with the process while the number 
of serious incidents declines.“2 This suggests that reporting of non-serious events could be 
used as an indicator of transfusion safety when serious events are simultaneously declining, 
assuming that better reporting is associated with safety awareness and good surveillance of 
patients, thus a lower actual risk. 
We studied whether the reports to the Dutch national haemovigilance system over a number of 
years support the assumption that a relatively high number of reported transfusion reactions 
in a hospital is associated with a lower likelihood of incorrect blood transfused (IBCT), taking 
this as a proxy for unsafe transfusion. We examined the outcome of the reporting of incorrect 
blood component transfused and analysed its associations with the rates of reporting 
transfusion reactions and different types of incidents. 
mATeRIALS AND meTHoDS
Study design 
We performed a nationwide study using data that had been reported by the 103 Dutch 
hospitals to the TRIP (Transfusion Reactions in Patients) Dutch National Hemovigilance Office 
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(see below). From the database we extracted figures of reported transfusion reactions and 
incidents in 2006-2010. For each hospital the reported transfusion reactions and incidents 
were analysed in relation to the annual numbers of transfused blood components (red blood 
cells, platelet concentrates and fresh frozen plasma). 
Transfusion setting
In The Netherlands there is a national blood service, Sanquin Blood Supply. In all but a few 
hospitals the blood transfusion laboratory holds a blood stock and performs blood grouping, 
immunohaematological investigations, blood component selection and compatibility testing, 
which may be in the form of electronic crossmatch. 
Haemovigilance reporting
TRIP Dutch National Hemovigilance Office has been operational since 2003. Each hospital has a 
designated haemovigilance officer, who is generally a chief biomedical scientist or consultant 
haematologist. Hospitals submit reports either electronically or using a paper reporting 
form. Each year hospitals are asked for data on numbers of transfused blood components, 
at which time hospitals also confirm whether reports for the previous year are complete. 
Haemovigilance reporting to TRIP covers all types and levels of severity of transfusion reactions 
as well as errors and incidents within the transfusion chain. These are collected using standard 
definitions which are similar to the international definitions as developed by the International 
Haemovigilance Network and the haemovigilance working party of the International Society of 
Blood Transfusion (see Table A in the web version of this article).7,8 The definitions for bacterial 
complications and that for severity grade 2 were modified slightly in 2008. Serious reactions 
are defined as those which are life-threatening or fatal or which cause long-term morbidity or 
(prolongation of ) hospital admission/morbidity.
Participation in haemovigilance reporting is regarded as the professional standard both in 
the national transfusion guideline and by the Healthcare Inspectorate.9 Participation by the 
hospitals has been approximately 95% each year from 2006. Since 2008, in accordance with 
European legislation, the reporting of serious adverse reactions and serious adverse events in 
parallel to the Healthcare Inspectorate as competent authority has been mandatory. Hospitals 
are also mandated to have a patient safety management system. TRIP publishes annual reports 
which are publicly available on the website (www.tripnet.nl). Annually there is considerable 
variation in the rate of reports in relation to the number of blood components transfused in a 
hospital.10






Reporting of transfusion reactions, errors and incidents occurs in three broad domains: the 
clinical/ward domain, the hospital transfusion laboratory and the patient safety domain. 
There is variation between hospital protocols regarding investigation. Notably some but not 
all hospitals go beyond the minimum requirements of the national guideline and perform 
investigations for mild non-haemolytic febrile reactions (temperature rise >1<2 °C without 
chills or rigors) and (mild) allergic transfusion reactions. 
Study outcome measures and statistical analysis 
We used submission to TRIP of one or more reports of incorrect blood component transfused 
by a hospital as a proxy for poor safety. Incorrect blood component transfused is defined as 
any case where the patient is transfused with a blood component which did not meet all the 
requirements according to the hospital protocol for a suitable transfusion for that patient, 
or that was intended for another patient. As a secondary outcome measure we analysed the 
reporting by a hospital of at least one unintentionally ABO-incompatible transfusion.
As reporting parameters for each hospital we calculated the rate of all reported transfusion 
reactions per 1000 blood components and defined tertiles of the reporting rate. We also 
calculated the rates per 1000 blood components of non-haemolytic transfusion reactions 
(≥ 2°C and/or rigors), of mild febrile reactions (>1<2°C) and of all other reported transfusion 
reactions with the exception of new erythrocyte allo-antibodies. Yes/no variables were defined 
for reporting of new allo-antibodies, of near miss and of other incidents. The presence of a 
transfusion safety officer was classified as none, 1-4 years or all years. We further defined four 
levels of annual total blood use: <3000, 3000-6000, 6000-13000 and >13000 units and three 
levels of the proportion of platelet units out of total blood use: <2.5%, 2.5-5% and >5%. For 
an assessment of any changes in absolute rates of reports we analysed 2006-8 and 2009-10 
separately, including all hospitals with at least four years of data.
Statistical analyses were performed using PASW Statistics 18.0.0 (SPSS inc., part of IBM 
Corporation, New York). The consistency of the rate of reported transfusion reactions 
in a hospital from year to year was assessed by performing linear regression of the rate of 
transfusion reactions in 2010 with that in 2009 and 2006-9 for all hospitals with four or five 
years of complete data, adjusting for the level of blood use. This was repeated without the 
adjustment but with exclusion of the hospitals transfusing fewer than 3000 units per year, as 
verification that the result was not driven by the smallest hospitals being least likely to have 
reported incorrect blood component transfused. To study the associations between reporting 
parameters and incorrect blood component transfused as well as reported ABO-incompatible 




Information on both transfusion reactions and total transfused units was available from 101 
of the 103 hospitals for one or more years in 2006-10, covering approximately 95% of national 
blood use. Table 1 summarises key figures about reporting according to the hospitals’ total 
blood use level. 






















<3000 34 336,087 1141; 3.39 1.35-4.32 36;   0.11 4;  0.012
3000-6000 21 630,605 2047; 3.25 1.76-4.56 51;   0.08 9;  0.014
6000-13000 32 993,668 3351; 3.59 2.14-4.73 74;   0.07 9;  0.010
>13000 14 1,384,157 4611; 3.33 2.21-4.74 144; 0.10 16; 0.012
a Average total units of blood components per year (red blood cells, apheresis or 5-donor pooled buffy coat 
platelets, fresh frozen plasma)
b Total of reported transfusion reactions, new allo-antibodies, errors and incidents
c Incorrect blood component transfused
Hospitals’ consistency from year to year 
Ninety-nine hospitals had four (n=6) or five (n=93) years of data and were included in this 
analysis. Table 2 presents the explained variance in individual hospitals’ rates of reported 
reactions in 2010 in comparison to rates of preceding years. Hospitals’ previous rates were 
good predictors of the 2010 transfusion reaction rate. Comparing the 2010 to the 2009 rate 
and that in 2006-8 with adjustment for blood use level gave a value of R2 of 0.55, indicating 
that approximately 55% of variance in the rate of reporting transfusion reactions is explained 
by the rates in the previous years. A similar result was obtained if only the hospitals transfusing 
over 3000 units per year were included. 
Table 2. Consistency of transfusion reaction reporting rate in hospitals
Linear regression with rate of 
transfusion reactions in 2010 
All hospitals (n=99)
Hospitals transfusing 
>3000 units p.a. (n=66)
R2 Significance R2 Significance
2009 rate 0.509 P<0.001 0.301 P<0.001
2006-2008 0.377 P<0.001 0.481 P<0.001
2009, 2006-2008 0.553 P<0.001 0.498 P<0.001
2009, 2006-2008 and blood use level 0.553 P<0.001
Trends in time
The total rate of reports to TRIP rose from 3.20 to 3.82 per 1000 blood components transfused 
from 2006-8 to 2009-2010, with the total number of transfusion reactions rising from 2.81 to 






3.34 per 1000 units (Table 3). This is partly explained by increased reports of allo-antibodies 
(from 0.93 to 1.20 per 1000 units). There were nonsignificant rising trends for reporting febrile 
reactions and for the total of transfusion reactions in other categories (data not shown). The 
overall rate of incorrect blood component transfused remained similar from 2006-8 to 2009-
2010 (0.096 and 0.092 per 1000 units in 2006-2008 and 2009-2010 respectively), as did that for 
ABO-incompatible transfusion (0.011 and 0.013 per 1000 units respectively). There was a rising 
trend of the rate of incorrect blood component transfused and unintended ABO-incompatible 
transfusion in the hospitals with the lowest rate of reported transfusion reactions and a 
declining trend in those with the highest rate (Table 3).
Table 3. Rates of reported transfusion reactions per period according to level of transfusion reaction 
reports
Level of hospital total transfusion reaction 
reportinga
2006-8 2009-10
Difference in rate  
(95% confidence interval)
Lowest (<1.8/1000 units; n=28)
 Total transfusion reactions














Middle tertile (1.8 - 3.7/1000 units; n=37)
 Total transfusion reactions














Highest tertile (>3,7/1000 units; n=34)
 Total transfusion reactions 















 Total transfusion reactions 














a Rate of reports per 1000 blood components transfused; hospitals are classified according to the average rate of 
transfusion reaction reporting in 2006-2010
whole period: odds of incorrect blood component transfused
The odds ratio for at least one report of incorrect blood component transfused rose with hos-
pitals’ annual blood use level and increased independently with higher levels of total transfu-
sion reaction reports. The odds ratio (OR) was 4.2 (95% confidence interval (CI) 1.3-13.7) for the 
highest vs. the lowest tertile after adjustment for blood use level (Table 4). Reported incorrect 
blood component transfused was also significantly associated with the highest tertile of mild 
non-haemolytic febrile reactions (>1 <2oC) and with a hospital’s reporting of allo-antibodies, 
near miss and/or other incidents. There was no association with platelet use level or with the 
proportion of serious reactions. 
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Table 4. Hospital reporting parameters and odds ratio (OR) of reported incorrect blood component 
transfused
Parameter 
(no. of hospitals; total n=101)
Incorrect blood component transfused
(IBCT; ≥ 1 per hospital)
No (%) 
with IBCT
Crude oR  
(95% confidence 
interval)
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a Average total units of blood components per year (red blood cells, platelets, fresh frozen plasma)
b Odds Ratio adjusted for blood use in four levels
c rate of reports per 1000 blood components transfused
d non-haemolytic transfusion reaction (≥ 2oC and/or chills/rigors); see definitions in Table A
e >1<2 oC; see definitions in Table A






In a multivariable logistic regression model which included blood use level, the presence of 
a transfusion safety officer and the reporting variables, reported incorrect blood component 
transfused remained independently associated with reporting of allo-antibodies, with near 
miss, and with other incidents; it was also associated with mild febrile reaction reporting (OR 
2.2, 95% CI 1.0-5.1; data not shown). Independently of the reporting of incorrect blood com-
ponent transfused, the parameters representing a relatively high rate of reports tended to be 
associated with each other as well as with the presence of a transfusion safety officer. 
Reported ABO-incompatible incorrect transfusion showed similar but weaker associations 
compared to all reported incorrect blood component transfused, both with and without 
adjustment for hospital blood use level (data shown in Table B in the web version of this article); 
because of the lower number of these reports the confidence intervals are wider.
DISCuSSIoN
In this study we first examined the consistency of hospitals’ rates of reported transfusion 
reactions. It was found that approximately 55% of the variation could be explained from the 
rates in earlier years thus there is considerable consistency from year to year. This probably 
reflects hospitals’ stable patient mix, transfusion reaction protocols and other factors relevant 
for reporting practice, e.g. safety awareness in the blood transfusion laboratory, nurse alertness 
and organisational safety culture. The consistency supports our pooling of each hospital’s data 
over several years.
As our main study question we investigated the hypothesis that higher numbers of less serious 
reports are an indicator for fewer very serious adverse transfusion reactions and events, as 
proposed in the 2009 SHOT Annual Report. We examined the reporting of incorrect blood 
component transfused as a proxy for unsafe transfusion and observed that this is more likely in 
hospitals which have a relatively high rate of reported transfusion reactions or which report to 
TRIP on allo-antibodies, on near miss or other incident(s). The breakdown of “total transfusion 
reactions” given in Table 4 shows that the positive association of reported incorrect transfusions 
with level of reports of transfusion reactions may be driven more by the reports of mild non-
hemolytic transfusion reactions than by those of non-hemolytic transfusion reactions. None 
of the associations is negative, i.e. none supports the hypothesis. While we cannot exclude 
the possibility that the hospitals with a higher rate of transfusion reactions may have more 
incorrect transfusions to report, a more likely explanation is that reporting of incorrect blood 
component transfused is more reliable in hospitals with strong awareness and reporting 
culture in the clinical areas, in the blood transfusion laboratory and in the domain of patient 
safety. In any case the data do not provide evidence that hospitals with higher rates of reported 
transfusion reactions are safer. The most serious incorrect transfusion events, those where 
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an ABO-incompatible unit is transfused, showed similar but non-significant associations. We 
observed no change in the overall rate of reported incorrect blood component transfused or of 
ABO-incompatible transfusions, nor was this demonstrated in the subgroup of hospitals with 
higher rates of reported transfusion reactions. The suggestive declining trend in the group 
with most transfusion reactions (Table 3) is driven by a small number of hospitals and should 
be interpreted with extreme caution. 
The SHOT comment refers to trends noted at the national level and could be explained by 
increased reporting by some hospitals coinciding with national improvement from adoption 
of recommendations. The question posed in this study examines whether the trend holds at 
the hospital level: if improvements are detectable, is it in the hospitals where rates of reported 
transfusion reactions are higher, where one regards this as an indicator that haemovigilance 
reporting is functioning well. What can explain our failure to demonstrate this – plausible and 
attractive – trend described by SHOT? Firstly, national haemovigilance reporting is a tool for 
monitoring events and not a direct means of improving safety. The Dutch system, launched 
in 2003, is relatively young and to date, neither the occurrence of the most serious reactions 
(Grade 3 and 4) nor that of ABO incompatible transfusions has shown any decline in the TRIP 
data. With the exception of TRALI following the male-only plasma intervention6 there has not 
yet been any improvement as regards the occurrence of serious transfusion reactions, but 
more notably also not of errors. 
The SHOT haemovigilance system was launched in 1996 and the declining trend of the 
proportion of transfusion-related serious morbidity and deaths has only gradually become 
apparent: the number of ABO incompatible red blood cell transfusions has dropped since 
approximately 2004 compared to the preceding eight years. The apparent improvement is 
ascribed chiefly to better application of safety procedures and recommended practices as 
laid down in national guidelines.11 Similarly the French haemovigilance system, active since 
1994, reports that the rate of ABO-incompatible transfusions leading to reactions was lower in 
2006-2010 than in 2000-2005, although the difference does not reach statistical significance.12 
In France the bedside ABO compatibility check by the transfusing nurse has been in place 
since 1985 and the bedside verification of patient and unit identity was designated as a 
distinct mandatory task by a ministerial circular in 2003. The trend of reduction of the most 
serious events in the world’s two oldest haemovigilance systems would be consistent with the 
explanation that it takes time for improved transfusion safety awareness, extra training and 
gradual implementation of recommended practices to lead to such improving trends.
The Dutch figures in absolute terms show that we must not seek the explanation in a greater 
safety level from the outset. The rate of total reported incorrect blood component transfused 






(2010 data) is 6.9 per 100,000 units distributed in the United Kingdom,13 probably similar in 
France (total of “serious adverse events with transfusion of LBP declared on the AR as Grade 0” 
and “serious adverse events with transfusion of LBP that caused an RAE of a grade >0” is 5.6 per 
100,000 units12) and 8.3 in The Netherlands. Ireland to our knowledge has the highest national 
rate of reported incorrect blood component transfused at 45 per 100,000 units14 (number of 
“SAE/IBCT” minus unnecessary transfusions and storage/expiry problems). The rates of ABO 
incompatible transfusion over the last four years are 0.38 in the UK, 0.36 in France, 1.13 in 
Ireland and 1.11 in The Netherlands (rates calculated from the annual reports 2,9,11,12). Of all 
events, the ABO-incompatible incorrect transfusions are among the most serious so should 
be least subject to under-reporting. The cited figures make it likely that reporting of incorrect 
blood component is not exhaustive in The Netherlands and secondly that there is room for 
improvement in the avoidance of ABO incompatible transfusions. We are not of the opinion that 
variation in reporting level could be reduced by regulatory requirements. In The Netherlands 
the overall rate of reports in 2006-10 ran at approximately 3 per 1000 blood components 
transfused, which is similar to or slightly above that in France with its mandatory system for 
reporting all transfusion reactions as well as serious adverse events in the transfusion chain. 
Regional variation in the rate of reporting has been noted both in the UK with reporting of only 
serious events but comparable regulations to The Netherlands, and France.12,13
A strength of this study is that it reviews several years of data in a haemovigilance system 
with near-complete participation. To our knowledge it is the first thorough analysis by a 
haemovigilance system of whether having more reports of transfusion reactions is an indicator 
for better hospital-level transfusion safety. It suggests greater reliability of reporting incorrect 
blood component transfused in hospitals with high levels of reports in various domains. In 
so far as success for a haemovigilance system depends on capturing information which will 
provide relevant signals to the transfusion professionals, this is in line with the statement that 
a successful haemovigilance system receives increasing numbers of less serious reports. 
The study is limited by the fact that we lacked knowledge of what specific hospital factors 
influenced reporting on the one hand, and transfusion safety on the other. A further possible 
limitation is the change of definitions in the course of the study period, however this did not 
affect the specific categories from which the analysed parameters were calculated. 
The cited comment in the SHOT 2009 report referred to the ratio of reports of very serious 
morbidity or death to the less serious events, as well as to a progressive (absolute) decline 
of ABO incompatible red cell transfusions. Our use of reported incorrect blood component 
transfused as an indicator for unsafe transfusion is a slightly different approach. These 
events (and among them, the ABO incompatible transfusions) constitute the most clearly 
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avoidable transfusion hazards, but are only one way in which transfusion can be unsafe. 
Avoidable transfusion reactions as another possible indicator merit future study, however 
only a minority of transfusion reactions (e.g. transfusion-associated circulatory overload) are 
currently avoidable by improvements in the clinical part of the transfusion chain. Avoidance of 
unnecessary transfusions represents a third dimension of safety with potential for improving 
patient outcomes and saving money. Reports of errors and incidents involving unnecessary 
transfusion are captured by some haemovigilance systems. Our haemovigilance system is 
soon to collaborate with hospitals to collect and provide benchmarking of basic indicators on 
observance of transfusion triggers.
CoNCLuSIoN
In conclusion, a high reporting rate of transfusion reactions is associated with increased odds of 
reporting incorrect blood component transfused. This may be explained by better surveillance 
and more complete reporting, although it cannot be excluded that hospitals with higher 
rates of transfusion reactions may have more incorrect transfusions to report. The data do not 
support the hypothesis that a higher rate of reporting transfusion reactions is an indicator for 
greater safety in the transfusion chain.
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Table A. TRIP (2008) definitions of transfusion reactions and incidents (published online only)
Nonhaemolytic transfusion reaction (NHTR) 
Rise in temperature of ≥ 2oC (with or without rigors/chills) during or in the first two hours after a transfusion, 
with no other relevant symptoms or signs; OR rigors/chills with or without a rise in temperature within the 
same time limits. No evidence (biochemical or blood group serological) for haemolysis, and no alternative 
explanation. 
mild (nonhaemolytic) febrile reaction
Rise in temp. >1°C (<2°C) during or in the first two hours after a transfusion with no other relevant symptoms 
or signs; optional reporting to TRIP. Haemolysis testing and bacteriology negative if performed. 
Acute haemolytic transfusion reaction
Symptoms of haemolysis occurring within a few minutes of commencement of until 24 hours subsequent 
to a transfusion: one or more of the following: fever/chills, nausea/vomiting, back pain, dark or red urine, 
decreasing blood pressure or laboratory results indicating haemolysis within the same period.
Biochemical haemolysis testing positive; blood group serological testing possibly positive; bacteriology 
negative.
Delayed haemolytic transfusion reaction
Symptoms of haemolysis occurring longer than 24 hours after transfusion to a maximum of 28 days: 
unexplained drop in haemoglobin, dark urine, fever or chills etc.; or biochemical haemolysis within the same 
period. Biochemical testing and blood group serology confirm this.
If new antibodies are found without biochemical confirmation of haemolysis, report as new allo-antibody. 
TRALI (Transfusion-related acute lung injury)
Dyspnoea and hypoxia within six hours of the transfusion; chest X-ray shows bilateral pulmonary infiltrates. 
There are negative investigations (biochemical or blood-group serological) for haemolysis, bacteriology is 
negative and no other explanation exists. Depending on the findings of tests of leukocyte serology, report is 
classified as immune-mediated or unknown cause.
Transfusion-associated circulatory overload (TACo)
Dyspnoea, orthopnoea, cyanosis, tachycardia >100/min. or raised central venous pressure (one or more of 
these signs) within six hours of transfusion, usually in a patient with compromised cardiac function. Chest 
X-ray consistent.
Anaphylactic transfusion reaction
Rapidly developing reaction occurring within a few seconds to minutes after the start of transfusion, with 
features such as airway obstruction, in and expiratory stridor, fall in blood pressure ≥ 20 mm Hg systolic and/
or diastolic, nausea or vomiting or diarrhoea, possibly with skin rash.
Haemolysis testing and bacteriology negative, test for IgA and anti-IgA. 







Allergic phenomena such as itching, redness or urticaria but without respiratory, cardiovascular or 
gastrointestinal features, arising from a few minutes of starting transfusion until a few hours after its 
completion. Haemolysis testing and bacteriology negative if performed.
New allo-antibody 
After receiving a transfusion, demonstration of clinically relevant antibodies against blood cells (irregular 
antibodies, HLA or HPA antibodies) that were not present previously (as far as is known in that hospital). 
Post-transfusion bacteraemia/sepsis
Clinical symptoms of bacteraemia/sepsis arising during, directly after or some time subsequent to a blood 
transfusion, for which there is a relevant, positive blood culture of the patient with or without a causal relation 
to the administered blood component. 
Post-transfusion viral infection 
A viral infection that can be attributed to a transfused blood component as demonstrated by identical viral 
strains in donor and recipient and where infection by another route is deemed unlikely. 
Haemosiderosis
Iron overload induced by frequent transfusion with a minimum ferritin level of 1000 micrograms/l, with or 
without organ damage. 
Post-transfusion purpura (PTP) 
Serious self-limiting thrombocytopenia possibly with bleeding manifestations (skin, nose, gastrointestinal, 
urinary tract, other mucous membranes, brain) 1-24 days after a transfusion of a red cell or platelet concentrate, 
usually in a patient who has been pregnant. Investigations: HPA antibodies and HPA typing of patient.
Transfusion-associated graft versus host disease (TA-gvHD) 
Clinical features of graft versus host disease such as erythema which starts centrally, watery diarrhoea, fever 
and rise in liver enzymes 1-6 weeks (usually 8-10 days) after transfusion of a T-cell containing (non-irradiated) 
blood component. Skin (and liver) biopsies can support diagnosis.
other transfusion reaction
Transfusion reaction which does not fit into the categories above
Incorrect blood component transfused (IBCT)
All cases in which a patient was transfused with a component that did not fulfil all the requirements of a 
suitable component for that patient, or that was intended for a different patient. TRIP requests institutions to 
report these cases, even if there are no adverse consequences for the patient.
Positive bacterial screen
The blood service reports a positive bacteriological screen, but bacterial contamination of the relevant 
material is not confirmed by a positive culture result on the same material or other products made from the 
same donation
Bacterial contamination of a blood component
Relevant numbers of bacteria in a (remnant of ) blood component or in the bacterial screen bottle of a platelet 
component, or in material from the same donation, demonstrated in the approved way with laboratory 
techniques, preferably including typing of the bacterial strain or strains. 
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Look-back by the supplier
Retrospective notification of a possibly infectious donation, leading to investigation of the recipient for that 
infection, but where no infection is demonstrated in the recipient. 
viral contamination of blood component
Retrospective analysis by Sanquin demonstrates viral contamination of an already administered blood 
component, previously screened and found negative.
Near miss 
Any error that, if undetected, could have led to a wrong blood group result or issue or administration of an 
incorrect blood component, and which was detected before transfusion.
Please indicate where the error arose, any further errors or failed checks, and how the error was discovered.
Haemolysed product 
Occurrence of clinical signs / symptoms in a patient associated with the presence of free haemoglobin in a 
transfused product (from recovered blood).
Heparinisation 
Clotting problems associated with incomplete removal of added heparin during automated blood recovery 
method.
other incident
Error or incident in the transfusion chain that does not fit into any of the above categories, for instance patient 
transfused whereas the intention was to keep the blood component in reserve, or transfusing unnecessarily on 
the basis of an incorrect Hb result or avoidable wastage of a blood component.






Table B. Hospital reporting parameters and odds ratios (OR) of ABO incompatible transfusion 
report(s) (published online only)
Parameter (no. of hospitals)
ABo incompatible transfusion reported (≥ 1 per hospital)
No (%) with ABo- 
incompatible Tf





























































































































































































a Average total units of blood components per year (red blood cells, platelets, fresh frozen plasma)
b adjusted for blood use in four levels
c rate of reports per 1000 blood components transfused
dNHTR-non-haemolytic transfusion reaction


















The chapters in this thesis concern various parts of the transfusion chain. In this general 
discussion we return to the main study question: is hemovigilance making a difference to 
safety in the transfusion chain? Hemovigilance is defined as “a set of surveillance procedures 
covering the whole transfusion chain from the collection of blood and its components to 
the follow-up of its recipients, intended to collect and assess information on unexpected 
or undesirable effects resulting from the therapeutic use of labile blood products, and 
to prevent their occurrence and recurrence”.1 There is considerable variation between 
hemovigilance systems and other players – notably hospitals, blood supply organisations 
and regulators – in the types of events examined, as well as in the inclusion of other activities 
focused on monitoring and improving safety in the chain. Since the impact of hemovigilance 
must vary according to what is done, we have listed components of hemovigilance in 
Table 1. The key component of hemovigilance is the collecting and analysing of reports 
of adverse reactions and adverse events with a view to making recommendations for 
improving safety. This will be the focus in the reflections which follow.
In this discussion we will consider the following four aspects of transfusion safety, which 
are of immediate relevance to donors on the one hand and to patients on the other.
1. Transparency and knowledge of risks
2. Avoidance of preventable adverse reactions
3. No mistakes
4. Appropriate blood use: sufficient and timely use of blood components according to 
current evidence, but only if truly indicated.
1. Transparency and knowledge of risks
It was the perceived lack of transparency and insight that triggered the move towards 
centralised hemovigilance data collection. This insight into transfusion risks is of value 
and a relevant part of transfusion safety when reporting of reactions and incidents is in 
place and the findings public. If there is failure to reduce hazards, this would not be a 
reason to cease collecting data - on the contrary the data are all the more essential in 
order to demonstrate the areas where action is needed. 
 
In chapter 1 it was seen that the European Union legislation (mandating data collection 
on blood product-related adverse reactions and adverse events from 2007) led to the 
introduction of national hemovigilance reporting in nine member states which did not 
previously have such a system. Patients can be assured that harms which have occurred 
are reported so lessons may be learned. If previously unknown adverse reactions occur, 
there is now a mechanism for these to be recognised and this opens possibilities for timely 
investigation and implementation of measures. 
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Collecting and analysing reports1 Serious reactions / suspected 
transfusion-transmitted 
infections (co)investigated by 
Sanquin2 as indicated
Primary process
Serious transfusion reactions 
Incl. TRALI
Only fatalities collected by the 
FDA, US
Yes Chapter 1, 7
Chapter 6
Non-serious transfusion reactions Yes Chapter 7
Transfusion-transmitted infection, 
confirmed
(Co)investigated by Sanquin Yes Chapter 1
Previously unrecognised (serious) 
transfusion reaction
Yes
New allo-antibody formation (after 
transfusion)
Yes Chapter 4
Incorrect blood component transfused, 
serious reaction
Requirement to report to 
Healthcare Inspectorate because 
of care quality issues
Yes Chapter 7
Incorrect blood component transfused, 
mild or no reaction
Hospitals: role of patient safety 
committee2
Yes Chapter 7
Near miss Yes Chapter 7
Patient outcomes following transfusion No
Divers incidents in hospital  




Recall re pos. bacterial screening







Blood salvage techniques 
No
Yes
Benchmarking information to  




Monitoring appropriate blood use
Info requested 
from hospitals




















  Hemovigilance staff
  Nurses









Yes (as submitted 
to Inspectorate)
No Chapters 2,3 
Long-term outcomes/ safety for donors No Chapter 4
Post-marketing surveillance of new 
blood component type
Producer’s responsibility Currently standard 
reporting only
1Non-exhaustive list
2Sanquin Blood Supply, national blood service in The Netherlands
3Patient safety committee
Hemovigilance fulfils the function of surveillance of blood components after their 
authorisation and the formal post-marketing (Phase 4) study. Interestingly, all but one 
of the 23 responding countries include reporting about serious adverse reactions in 
blood donors, although this is not strictly required in law. Nevertheless the usefulness of 
collecting – and publishing – hemovigilance data depends on the validity of the collected 
information. Several European Union member states were found to have seriously 
incomplete or undocumented coverage of reporting organisations. The European (non-
binding) guidance document provides definitions for types of transfusion reactions, based 
on those of the International Society of Blood Transfusion (then still in draft form) and the 
SHOT definition for transfusion-transmitted infection. The survey showed that half of the 
countries did not receive supporting information with all the serious reports thus were 
not able to consistently validate them against the internationally adopted definitions. 
In The Netherlands the TRIP reports largely meet the objective of transparency. There is 
high participation by hospitals (though not 100%) and a policy of expert review of serious 
transfusion reactions. Concern regarding uniformity of data collection still exists, however. 
In the assessment of complex cases discussion frequently arises between experts about 
the most likely diagnosis of a transfusion reaction, for instance a suspected TRALI, even 
though a definition exists and when sufficient clinical information is available.2,3 The rating 
of the severity of a reaction and its imputability to the blood transfusion can capture 
some of the variation between cases – as well as give rise to further debate between 
hemovigilance professionals. Such detailed assessment of reports is chiefly relevant for 
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serious reports, as opposed to non-serious ones which are less likely to trigger major 
preventive measures. 
Chapter 3 provided insight into the complications of whole blood donation in The 
Netherlands and is the first published large-scale analysis of the national donor 
complication data. In the blood supply organisation there is full participation by collection 
centres, which use standard operating procedures. Despite the limitations of routinely 
– perhaps variably – recorded data, the data give real-life information which was not 
previously available. 
The primary result of central reporting of adverse reactions and incidents is to obtain a 
picture of what the short-term hazards are. This can show up the types of reaction which 
are causing a heavy burden of harm or demonstrate a previously unknown or less common 
problem. Attention can be drawn specifically to those reactions which can be prevented, 
as well as to the types and causes of errors and incidents. In order to progress beyond 
the stage of merely counting events additional information, either captured by the 
hemovigilance system or obtained from other sources, is needed. Areas to be considered 
are denominator data regarding donations or transfusions without adverse reaction or 
mishap; characteristics of donors and patients, component production parameters and 
specifications, information about hospital laboratory and clinical transfusion practices. 
Meanwhile, the specifications of the system vary considerably between countries 
(chapter 1, annexes) and with them, the scope and level of detail of the insights which 
can be obtained. The system must be appropriate to the setting, for instance a low human 
development index country where women die from peripartum blood loss should first 
ensure availability of tested blood and only then set up a basic hemovigilance system to 
capture just the serious reactions and errors. In a country with adequate resources there 
is a lack of evidence to guide the decision of which areas to include. While there is wide 
consensus about capturing serious reactions, some professionals would question the 
nationwide collecting of reports of known minor side effects of blood transfusion such as 
febrile or allergic reactions. Others believe in the value of these reports as an indication 
that the system is working or as a comparator category to support interpretation of a 
decline of another category as a true improvement.4 It is clear that minor reactions have 
a practical and economic impact in the hospitals – TRIP is currently performing a cost 
analysis of the reported reactions. An incremental cost-effectiveness analysis of collecting 
additional types of reports at national level is impossible to perform: any improving trends 







2.  Avoidance of preventable adverse reactions
The objective is to reduce those adverse reactions which are amenable to prevention. This 
could be through general measures or through targeted precautions in donors or patients 
who have risk factors for harm. The findings of chapter 3 are relevant for counselling donors 
who faint or experience a venepuncture-related problem at their first donation, who 
wish to know how to avoid having the same problem next time. A general intervention 
could be to develop improved donor information material using the results of the study, 
providing tips for preventing possible complications and discussing the (increased, but 
still low) risk of recurrence at the next donation. Provision of such information can already 
reduce the occurrence of complications and improve donor retention.5 The routinely 
recorded complications will be useful for monitoring the rates following the intervention. 
Chapter 4 describes the only study in this thesis which actively investigated long-term 
outcomes. It was started in 2004 at the time when Sanquin Blood Supply and the donor 
registry Europdonor Foundation authorised the use of granulocyte colony stimulating 
factor (G-CSF) for mobilisation and harvesting peripheral blood stem cells in healthy 
unrelated donors. This guideline lays down several precautionary restrictions for exposure 
to G-CSF, e.g. an upper age limit of 55 years. The study, conducted among related donors, 
specifically examined whether such restrictions enhance safety. Reassuringly there was 
no suggestion of long-term increased risks of malignancy or cardiovascular disease but 
the number of follow-up years was (far) too small to exclude an increase. International 
collaboration in capturing donor follow-up data will be necessary to come nearer to 
an answer to these theoretical concerns. The results of our study highlighted the fact 
that the donor screening criteria for unrelated donors effectively select those at lower 
cardiovascular risk, which led us to recommend following the same criteria for related 
donors. We also found that female donors were more likely to require two days of apheresis 
or a central venous catheter: an aspect which can be weighed in selecting a preferred 
donor for the procedure, obtaining the best balance between the burden to the donor 
and prospect of benefit to the patient. The study is part of an investigative protocol which 
also evaluates the donation procedure and its acceptability for prospectively included 
unrelated and related donors. Recruitment of donors to the study has been concluded 
and analyses are to be performed in 2013 after the 1-year follow-up.
The pilot case-control study described in Chapter 5 suggested a number of risk factors 
for the development of red cell antibodies, including the presence of solid malignancy 
which had not previously been implicated. This study required laborious collection of 
additional clinical patient information. A limitation of the routine hemovigilance reports 
is that they capture very little patient data: in The Netherlands chiefly the specialty of 
the prescribing doctor and the indication (e.g. chronic symptomatic anemia or clotting 
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factor deficiency) while free text information can be added on main clinical diagnosis 
and clinical condition. Scope for future studies would be greatly increased by making use 
of other routine sources of data, such as hospital treatment episode administration. For 
the present, risk factors for the development of allo-antibodies have become one of the 
ongoing areas of investigation for the research departments at Sanquin Blood Supply and 
Leiden University Medical Center.6,7
Chapter 6 demonstrated the improvement in safety following a measure to reduce the 
risk of Transfusion-related acute lung injury (TRALI). It was partly through hemovigilance 
worldwide that there was an increase of awareness and research on mechanisms of this 
previously described transfusion complication. Based on the role of anti-leukocyte (HLA 
and HNA) antibodies many countries have introduced measures to reduce the risk of 
TRALI. In The Netherlands this was the male-only plasma measure, effective from mid-2007 
(quarantine fresh frozen plasma being the type of plasma product used in this country 
from 2002 to 2012). This gives an example of using hemovigilance data to complete the 
quality cycle: a problem is noted, a measure is taken and the ongoing reporting monitors 
the effects of change. A caveat exists, however. Hemovigilance reporting is essentially 
a form of spontaneous reporting as opposed to active monitoring as in clinical trials. 
Spontaneous reporting is subject to inconsistency and incompleteness so a change of 
rates must always be analysed, as we did in chapter 6, against comparison cases in order 
to plausibly take account of possible shifts in reporting tendencies.
3. No mistakes
Has hemovigilance activity in The Netherlands been associated with a reduction of 
transfusion errors? This was examined in chapter 7. Hospitals with a high rate of reported 
transfusion reactions were found to also have a greater likelihood of having reported 
an incorrect blood component transfused. This would be consistent with not all errors 
being detected or reported in hospitals with a less strong reporting culture, which could 
partly arise from differences of interpretation about what types of event are reportable 
errors, despite the availability of definitions.8 The Dutch data showed no decline in the 
numbers of reported incorrect transfusions or of the most serious subgroup, that of the 
ABO-incompatible transfusions. This is in contrast to the United Kingdom and to France 
where there have been declining trends of the reported ABO incompatible transfusions. 
(Note however that the number was again higher in the recently published SHOT 2011 
report, though the rate in the UK remains lower than in The Netherlands.) No country has 
seen widespread introduction of electronic technology for the prevention of errors so any 







It must be appreciated that hemovigilance reporting serves for surveillance of adverse 
reactions and of errors and incidents. The act of reporting is not an intervention to actually 
reduce risks, although the assumption is that feedback to the transfusion professionals 
on what is happening, combined with recommendations for practice, may lead to 
improvements in safety. A priori it cannot be assumed that the hospitals which detect 
and send in higher numbers of reports of febrile and other reactions should make less 
mistakes in sample collection, component selection or identifying patients at the bedside. 
Even so it was disappointing that we failed to demonstrate better safety in the supposedly 
vigilant hospitals with higher rates of reported transfusion reactions. Maybe there truly 
is no association between the rate of reported transfusion reactions and the level of the 
vigilance or adherence to protocols in the hospital. Or was the reporting of incorrect 
blood component transfused not an appropriate proxy for unsafeness of transfusion, 
perhaps because reporting is indeed inconsistent? Avoiding incorrect transfusions is 
highly important but only part of transfusion safety. For now it remains an unanswered 
question whether certain hemovigilance data (preferably easy to collect) are usable as an 
indicator of safe practice.
4. Appropriate blood use
Sparing use of blood transfusion is important for both for donors and for patients. Donors 
have no demonstrated health benefit from their donation. The national burden to donors 
should be limited to the lowest which is compatible with the “good” for which they 
accept the inconveniences and small risks of donation: the availability of a safe, effective 
transfusion service. For patients, numerous studies have shown better outcomes when a 
restrictive transfusion policy is in place. It is also clear that adverse reactions and incidents 
in the transfusion chain will be immediately avoided by reducing blood use.
In the era of hemovigilance, capture of national figures on blood transfusion by 
international bodies including the Council of Europe has highlighted large differences in 
the number of components used, a twofold difference in the consumption of red blood 
cell concentrates per 1000 in the population being apparent between countries with well-
developed healthcare systems.9 Table 2 summarises the data for a number of countries 
with Ireland, France and The Netherlands showing the lowest consumption in western 
Europe. Interestingly, the rate was lowest in France in 2002, when a study of anesthetic-
related mortality from that country reported 200 deaths per year from delayed blood 
transfusion or failure to transfuse.10 The cause was related to delay in requesting and 
logistic problems but not to the transfusion triggers which were applied. Since then there 
has been an increase in the parameter in France. In Denmark, the country with the highest 
consumption in 2003-4, nationwide actions have brought about a noteworthy decrease 
in blood use.9,11 In the years to come, through growth in the numbers of elderly people 
in populations, increasing blood requirements are to be expected even with thrifty use.12 
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Table 2. Numbers of units of red blood cell concentrate distributed per 1000 inhabitants (source: 
see ref. 9) 
uk France Ireland Netherlands Denmark
2001 46.2 33.0 30.1 37.7 62.3
2002 45.1 31.8 - 39.2 -
2003 43.7 32.4 - 37.6 70.8
2004 41.4 32.8 34.8 36.6 72.9
2005 39.5 32.1 32.9 35.5 63.5
2006 - 33.1 32.7 34.0 67.0
2007 35.8 - 35.3 33.8 64.0
2008 36.3 - 31.8 34.2 60.0
Although hospital hemovigilance staff are very much implicated in the area of auditing 
the appropriateness of prescribed blood transfusions it is not currently within TRIP’s 
mandate (or that of other hemovigilance systems) to analyse data on blood use 
except as a denominator for the reports. However it is known from analysis of reports 
of transfusion reactions that sometimes the actual prescription of the transfusion was 
debatable or incorrect according to accepted transfusion indications.13,14 Also some 
reports to TRIP concern incidents which led to inappropriate or unnecessary transfusion 
or avoidable component wastage. These incidents are captured in the category of other 
incident and have been highlighted in recent TRIP reports. The (2011) revised national 
transfusion guidelines include recommended quality indicators for blood transfusion.15 
The guideline development group has requested TRIP to evaluate these in collaboration 
with the hospitals. Although still under development they can potentially provide a tool 
for hospitals to monitor their own practice against that of other hospitals. For this work, 
the strength of a national office with an established network of contacts within hospitals 
is self-evident. 
In conclusion, we have shown that hemovigilance reporting is improving knowledge 
about the occurrence of adverse reactions and incidents in the transfusion chain. 
Demonstration of actual safety improvement since TRIP started at the end of 2002 has 
been limited to the effect of the male-only plasma measure for TRALI reduction. The 
observational data are bound by limitations of data quality and variable reporting and do 
not capture longer-term outcomes. After ten years of national hemovigilance reporting 
in The Netherlands we do not know whether capturing hemovigilance data by a hospital 
or a country contributes to obtaining more favourable patient outcomes, or which form 








International tools, data sharing and comparisons
Internationally recognised instruments are necessary for classifying data in a harmonized 
way. The International Haemovigilance Network and the Haemovigilance working party of 
the International Society for Blood Transfusion (ISBT) have usefully published surveillance 
definitions for donor complications and non-infectious transfusion reactions.16 Definitions 
for infectious transfusion complications have proved more intractable (these are being 
developed by the ISBT working party on transfusion-transmitted infections) but work is 
progressing. Comparison of rates of reported errors and incidents is seriously hampered 
by differences in classifications between countries. (This includes the mandatory EU 
reporting, where the definitions and guidance document are not uniformly interpreted). 
The ISBT hemovigilance working party should continue its project of drawing up 
definitions for surveillance of sentinel types of errors. The ISBT working party on clinical 
blood use has assumed the task of developing an agreed and validated way of classifying 
patients’ medical conditions and of indications for blood transfusion. Such international 
groups should make strong statements about the need for monitoring data quality.
Under the auspices of the International Haemovigilance Network a reporting database for 
aggregate national hemovigilance data has been launched: the International Surveillance 
database for Transfusion Adverse Reactions and Events, ISTARE.17 Currently the first year 
of digitally captured data is being analysed. In the pilot phases there were wide variations 
between countries’ data. The ISTARE steering group envisages taking up data quality issues 
with the participating countries and planning more in-depth analyses. The differences 
between countries in donation volumes and in blood component types will constitute a 
limitation. Such international comparisons are likely to encourage gradual harmonisation 
of categorisation and trigger further specific research projects by (groups of ) participants. 
A future development may be sharing line-by-line data between donor or recipient HV 
systems so that specific questions can be investigated.
making data more accessible
As stated, hemovigilance reporting is not in itself a direct means to improve safety. It can 
only contribute to improvements if information is made available to those who organise 
or perform tasks in the transfusion chain. In the short term, effort is needed to make 
information accessible, e.g. turning routinely collected donor complication information 
into “dashboard” information for blood collection centre managers. TRIP hopes to develop 
interactive features in the online reporting database so that hospitals can generate 
graphs showing their own rate of certain types of complications against national figures. 
Chapter 8
130
Currently it cannot be said whether there is an optimal rate of a particular type of reports 
which is associated with transfusion safety, so the time is not ripe for hemovigilance data 
to be used as performance indicators which might be made public. 
TRIP could perform more analyses if better “denominator” information were available about 
transfusion recipients who do not suffer from adverse reactions. Different groups have an 
interest in transfusion-related research and reported transfusion reactions. For instance, 
Sanquin must conduct post-marketing surveillance of newly introduced component 
types. Linking of transfusion data to patient survival using population mortality data (with 
encryption mechanisms to meet privacy requirements) was employed in the PROTON 
study18 and a larger follow-on study is in preparation. It is essential to collaborate so that 
– while guaranteeing donors’, patients’ (as well as practitioners’ and hospitals’) privacy – 
duplication is avoided and effort invested in collecting data leads to the best possible 
returns. Types of routinely collected data which have recently been explored (but not 
yet in The Netherlands) are those of hospital episode statistics and health care insurance 
claims data.19,20 Appropriate mechanisms will be needed, while protecting individuals’ 
privacy, to enable healthcare professionals and organisations to harness information on 
transfusion practice and link this with extended donor and product data for studying and 
improving donor and patient outcomes. 
Patient outcomes
At present hemovigilance reporting only covers the occurrence of transfusion reactions or 
incidents. What matters more are patient outcomes following transfusion. The literature 
on effects of the removal of white blood cells (leukoreduction) from transfused blood 
components was recently reviewed.21 While it is clear that febrile reactions, formation 
of HLA antibodies and the risk of cytomegalovirus transmission are all reduced when 
leukoreduced blood components are transfused, the review questions the possible 
effects of leukoreduction on postoperative infections, aggravation of multi-organ failure 
or cancer recurrence, the only exception being a demonstrated 50% reduction of short-
term mortality from leukoreduction of blood components in cardiac surgery. It remains 
far from clear what transfusion practices are best for patient outcomes and a matter of 
speculation whether there are links between occurrence of transfusion reactions and 
patients’ longer-term immunological status and health. Studies of relevant outcomes are 
needed in different groups of patients in order to investigate the impact of transfusion 







Links to vigilance in other domains
Numerous stakeholder organisations in hemovigilance, which in The Netherlands include 
TRIP, the Healthcare Inspectorate and Sanquin Blood Supply, are also involved with 
activity and vigilance in the domain of human tissues and cells. The overlap of interests 
concerns the types of hazard, the donors who may make different types of donations 
and the common methodology for hemovigilance and tissue and cell vigilance. At the 
time of writing it is not clear how The Netherlands will ensure links between vigilance 
and surveillance procedures relating to organs for transplantation as required under 
the European Directive 2010/53/EU (formerly Directive 2010/45/EU; to be transposed 
into European Union member states’ national legislation by 27th August 2012). This will 
clearly require new loops in the network of collaboration between relevant stakeholder 
organisations.
While links between hemovigilance for blood and biovigilance for tissues, cells and 
organs have obvious relevance, it is no less relevant to create or strengthen links with 
pharmacovigilance and the “vigilance” of medical devices. In many countries the 
competent authority responsible for hemovigilance also deals with biovigilance as well as 
medicines, however the expertise may lodge in different departments with little contact 
between them. In The Netherlands TRIP initiated an agreement for collaboration with the 
Dutch medicines adverse reaction agency, Lareb, because of areas of common interest 
regarding plasma-derived medicines and medicines used in patient blood management. 
When SD-plasma (solvent-detergent treated plasma) is reintroduced (as is likely to happen 
in 2013) this collaboration will be the basis of the reporting instructions communicated to 
the hospitals for adverse reactions or incidents which may arise with its use. Information 
from medical device vigilance reporting is currently not accessible to the hemovigilance 
office, but the possibility of links should be explored. Such collaboration could lead to 
speedier results, as for instance in promoting design modification of apheresis devices 
for improving donor safety,23 and improve information and transparency about recipient 
adverse reactions from use of autologous drain blood reinfusion devices or new 
technologies.
Hot or cold hemovigilance?
Some reporting systems require timely reporting of certain types of event, notably where 
speedy corrective action can prevent or reduce harm. This is the case for cases needing 
investigation and/or look-back by the blood service. In The Netherlands early reporting to 
the inspectorate is mandatory in cases of very serious patient harm from safety incidents. 
TRIP, a passive reporting system, has politely but repeatedly requested hospitals to submit 
their reports more promptly. Regrettably, on a number of occasions the response to 
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queries about serious reports only reached TRIP in the form of publications. TRIP has so 
far failed to present its annual report earlier than October or November of the following 
year and this means the information and recommendations are always retrospective. For 
hemovigilance and the link with other types of vigilance to have more practical relevance, 
TRIP should explore ways of maintaining its role as a safe, professionally based agency but 
becoming an active partner with other organisations, contributing its expertise in looking 
for and promoting ways to improve safety for donors and patients. 
Polder model vigilance, “we do it together”
As discussed above, hemovigilance reporting does not in itself improve transfusion 
safety. The collating of transfusion reaction and incident reports can primarily be used to 
improve transparency and make professionals more aware of what is going on. Top-down 
mandatorily imposed data capture by no means always achieves even that. Evidence is 
largely lacking to state criteria for a hemovigilance system which will be “effective” for 
reliably providing insights on which to base recommendations. We are equally uncertain 
about the most effective ways of disseminating the basic data and recommendations of 
hemovigilance, in order to trigger change.
For the time being, the TRIP system – launched at the end of 2002 on the basis of expert 
opinion and subsequently essentially unchanged – should critically review its methods. 
It is essential to look for the most efficient methods of data collection to minimise the 
burden of reporting for hemovigilance staff and combat the risk of reporting fatigue, 
particularly at a time of cutbacks in healthcare. For TRIP, it will require both creativity and 
extra work to actively pursue optimisation of the system.
Hemovigilance should be considered in the broader sense of surveillance and promoting 
quality of the transfusion chain. The stakeholders range from senior blood service quality 
staff who pursue the results of look-back investigations to donor attendants who provide 
social distraction to inexperienced and fearful blood donors so that they have a relaxed, 
successful donation experience. They include hospital managers who back the work 
of transfusion safety officers in monitoring blood utilisation, Healthcare Inspectorate 
staff who can mete out “push” to those who would otherwise place requirements of 
hemovigilance to the bottom of their priority list, professionals who prescribe blood 
components and nurses who administer them. Hemovigilance should be seen as an 
activity and a focus, rather than an end in itself. All stakeholders should play their part while 
respecting other people’s roles and responsibilities. Then we will be able to progressively 
develop hemovigilance in the fashion of a polder model so that we achieve the greatest 
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Hemovigilance has been widely introduced and promoted. By collecting reports of adverse 
transfusion reactions and of transfusion errors or incidents, it aims to conduct surveillance of 
transfusion safety, make recommendations and bring about improvements in safety of blood 
components and practice in the transfusion chain. In the European Union (EU), member states 
are mandated to have a hemovigilance system for reporting of serious adverse reactions and 
events which might have links with the component quality or safety. Nine out of 23 countries 
responding to a descriptive minisurvey set up new systems to compliance with this legislation 
(chapter 1). At present completeness and quality of the data are uncertain in some countries.
Data on donor adverse reactions is an integral part of hemovigilance (chapter 2). Though not 
part of mandatory EU reporting, it is collected by nearly all national hemovigilance systems 
in the EU. In The Netherlands, Sanquin Blood Supply now analyses and for the first time has 
published findings from the routinely collected donor adverse reaction data (chapter 3). 
Analysis of procedural and follow-up data in a cohort of related peripheral blood stem cell 
donors raised no concern of unacceptable safety but highlighted the fact that the donor 
screening criteria for unrelated donors effectively select those at lower cardiovascular risk 
(chapter 4), which led us to recommend following the same criteria for related donors.
In the domain of recipient hemovigilance, an exploratory case-control study found previously 
undescribed associations of reported new allo-antibody formation following transfusion with 
patient characteristics (chapter 5). As well as generating hypotheses for larger studies, this 
demonstrated the usefulness and feasibility of using hemovigilance data in conjunction with 
more extensive patient data. The ongoing national hemovigilance registration was directly 
employed to calculate the reduction in risk of TRALI following a change of blood component 
specifications, viz. the implementation of male-only plasma (chapter 6). This analysis employed 
the reported cases not associated with transfusion of plasma to adjust for reporting trends. 
It was estimated that the total burden of reported TRALI was reduced by approximately one 
third. Since the launching of Dutch national hemovigilance reporting this is the only area 
where a reduction of risk has been demonstrated. It has been postulated that a successful 
hemovigilance system sees more non-serious reports while the reports of serious harm go 
down. In The Netherlands, an analysis of hospital-level data found that hospitals reporting a 
relatively large number of mainly non-serious transfusion reactions do not appear to be safer 
for transfusion, as measured by the fact that they also were more likely to have reported a 
transfusion error (chapter 7). Also the TRIP data up to and including 2010 show no tendency of 
reduction of either serious transfusion reactions or of errors. 
Overall, the hemovigilance activity described in this thesis has provided increased insight in the 
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adverse reactions and incidents regarding both donors and recipients of blood components. 
Donor and patient care can now benefit from knowledge of Dutch data, however hemovigilance 
itself has not brought about any reduction of risks. Longer-term risks are not addressed by 
standard hemovigilance data collection. Collaboration and combining hemovigilance data 
with further data sources on donors, blood collection and component parameters, patient 
characteristics, hospital practices and relevant outcomes are needed to realise more of the 




Hemovigilantie is in veel landen ingevoerd en gepromoot. Het doel is om door het verzamelen 
van meldingen van ongewenste transfusiereacties en van fouten of incidenten in de 
transfusieketen de veiligheid van bloedtransfusie te monitoren, en aanbevelingen te doen 
voor verbetering van de veiligheid van bloedproducten of van praktijken in de transfusieketen. 
In the Europese Unie (EU) moeten lidstaten een systeem hebben voor het melden van ernstige 
ongewenste reacties of van incidenten die mogelijk een relatie hebben met kwaliteit en/
of veiligheid van bloedproducten. Negen van 23 Europese landen die respondeerden op 
een korte descriptieve survey hadden een nieuw systeem opgezet om aan de wetgeving 
te voldoen. Momenteel zijn de mate van volledigheid en de kwaliteit van de gegevens in 
sommige landen onduidelijk.
Informatie over nadelige reacties bij bloeddonors maakt deel uit van hemovigilantie (hoofdstuk 
2). Ondanks dat het niet valt onder de EU meldverplichting, worden deze gegevens verzameld 
door bijna alle landelijke meldsystemen in de EU. In Nederland worden de routinematig 
vastgelegde gegevens over donorcomplicaties nu door de bloedvoorzieningsorganisatie 
Sanquin geanalyseerd en er is voor het eerst over gepubliceerd (hoofdstuk 3). Een analyse 
van procedureproblemen en follow-up informatie in een cohort van verwante perifere bloed 
stamceldonors gaf geen aanwijzing voor onaanvaardbare risico’s. De studie maakte duidelijk 
dat de donor screeningscriteria voor onverwante stamceldonatie effectief zijn in het selecteren 
van donors die een lager cardiovasculair risico hebben (chapter 4), hetgeen reden was om aan 
te bevelen deze criteria ook te volgen bij de keuring van verwante donors.
In het domein van hemovigilantie bij ontvangers van bloedtransfusies toonde een verkennende 
case-controlestudie associaties tussen gemelde nieuw gevormde antistoffen en bepaalde 
patiëntkarakteristieken die niet eerder waren beschreven (hoofdstuk 5). Naast het genereren 
van hypotheses voor grotere studies, bewees deze studie het nut en de haalbaarheid van 
gebruik van hemovigilantie in samenhang met uitgebreidere patiëntgegevens. 
De doorlopende nationale registratie van hemovigilantiegegevens werd direct toegepast om 
de afname van het risico op TRALI te berekenen na een wijziging in de specificaties van een 
bloedproduct, t.w. de implementatie van vers bevroren plasma afkomstig van mannelijke, nooit 
getransfundeerde donors (hoofdstuk 6). In deze analyse werden de gemelde TRALI’s waarbij 
geen plasma was getransfundeerd, gebruikt om te corrigeren voor wijzigingen in het melden 
van deze complicatie. De afname van het totale aantal gemelde TRALI’s bedroeg volgens deze 
methode ongeveer éénderde. Sinds het begin van het Nederlandse hemovigilantiesysteem 
is dit het enige voorbeeld van afname van het risico op een type bijwerking. Men heeft 
gesteld dat een succesvol hemovigilantiesysteem te herkennen is aan toename van niet-
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ernstige meldingen terwijl de ernstige meldingen dalen. In Nederland toonde een analyse van 
meldingen aan TRIP in 2006 – 2010 op ziekenhuisniveau dat ziekenhuizen met een relatief 
groot aantal van voornamelijk niet-ernstige meldingen van transfusiereacties ook meer kans 
hadden om een of meer transfusiefouten te hebben gemeld (hoofdstuk 7). Het melden van een 
transfusiefout kan beschouwd worden als teken van onveiligheid in de transfusieketen. Het is 
op dit moment onbekend of ziekenhuizen met meer meldingen van transfusiereacties ook 
meer fouten te melden hadden, of dat de fouten beter gedetecteerd en doorgemeld werden 
aan TRIP. Er was in de TRIP gegevens tot en met 2010 geen dalende tendens van fouten, noch 
van ernstige transfusiereacties met uitzondering van TRALI.
Over de hele linie genomen, heeft de hemovigilantie aktiviteit die in dit proefschrift 
beschreven is, inzicht gegeven in het optreden van transfusiereacties en van incidenten zowel 
bij bloeddonors als bij ontvangers van bloedproducten. Er zijn aanbevelingen gedaan voor 
verbeteringen in selectie van bloedproducten, in monitoring van patiënten en organisatie 
van de transfusieketen. De zorg van donors en van patiënten kan nu mede gebaseerd 
worden op Nederlandse gegevens. Echter het is niet aangetoond dat door hemovigilantie 
de risico’s zijn afgenomen. Langere-termijn risico’s worden niet in kaart gebracht door de 
standaard dataverzameling van hemovigilantie. Meer samenwerking en het combineren 
van hemovigilantiedata met aanvullende bronnen van gegevens over donors, bloedafname 
en bloedproduct, over patiënt eigenschappen en relevante patiëntuitkomsten en over 





Afssaps  Agence française de sécurité sanitaire de produits de santé
ALI  acute lung injury, acute longschade
ANSM  Agence nationale de sécurité du médicament et des 
  produits de santé (France)
Bc  blood component
BE, blood establishment organisation which performs collection, testing and/or processing 
  of blood or blood components
BMI  Body mass index
CBO  CBO quality organisation in healthcare (Netherlands)
CI  confidence interval
Competent authority National regulatory authority for blood and blood
  components
CVC  central venous catheter
CVD  cardiovascular disease
EFS  Établissement Français du Sang
EU  European Union
FDA  Food and Drug Administration (United States)
FFP  fresh frozen plasma
FU  follow-up
G-CSF  granulocyte colony stimulating factor
Hb  hemoglobin
HLA  human leukocyte antigen
IBCT  incorrect blood component transfused
IGZ  Inspectie voor de Gezondheidszorg (Healthcare 
  Inspectorate, Netherlands)
IHN  International Haemovigilance Network
IQR  inter-quartile range
ISBT  International Society for Blood Transfusion
ISTARE  International Surveillance Database for Transfusion-Associated 
  Reactions and Events
MHRA  Medicines and Healthcare Products Regulatory Agency
  (United Kingdom)
NHTR  non-hemolytic transfusion reaction
NMDP  National Marrow Donor Program (United States)
OR  Odds Ratio
PAR  population attributable risk
PBPC, PBSC peripheral blood progenitor cells, peripheral blood stem cells
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Plts  platelets, platelet concentrate
PTP  post-transfusion purpura
Q-FFP  quarantine fresh frozen plasma
RBC  red blood cell concentrate
SAE  serious adverse event
Sanquin  Sanquin Blood Supply Foundation
SAR  serious adverse reaction
SD  solvent detergent (virus-reducing treatment)
SHOT  Serious Hazards of Transfusion 
  (United Kingdom Hemovigilance scheme)
SOP  standard operating procedure
SMR  standardized morbidity ratio
Tf  transfusion
TR  transfusion reaction
TRALI  Transfusion-related acute lung injury
TRIP  TRIP Foundation (Transfusion Reactions In Patients)
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Het is een voorrecht geweest om aan dit proefschrift te werken. Behalve dat ik er veel van heb 
geleerd heb ik met vele collega’s mogen samenwerken. Ik hoop dat ik ook in de toekomst zal 
kunnen rekenen op hun enthousiasme, inzet en vriendschap. 
Mijn onderzoekstraject begon toen ik aan Arlinke Bokhorst, inmiddels directeur van TRIP, en 
toenmalige directeur Lejé Zeeman meldde dat ik graag onderzoek zou willen verrichten op 
het gebied van donorzorg met als doel een dissertatie. Hun belangrijke steun en hulp heeft 
al het volgende in gang gezet. Zo werd ik doorverwezen naar Anneke Brand, de promotor die 
iedere promovendus zich wensen mag. Later werd door mijn benoeming bij TRIP het beoogde 
werkgebied uitgebreid tot de transfusieketen en de ontvangers van bloedproducten; Martin 
Schipperus verklaarde zich bereid het copromotorschap op zich te nemen. Dit was niet alleen 
onmisbaar voor dit proefschrift, ook heeft Martins passie voor het klinisch onderzoek een 
belangrijke dimensie toegevoegd in de ontwikkeling van het TRIP meldsysteem. Het team 
werd gecompleteerd door Anske van der Bom. Anneke, Martin en Anske, jullie zijn voor mij 
een ideale trio geweest, altijd een bron van kennis, inspiratie, referenties, nuttige feedback en 
persoonlijke aandacht.
Het TRIP bestuur ben ik erkentelijk voor hun acceptatie van het promotietraject dat deels 
gebaseerd zou worden op onderzoek bij TRIP. Cees van der Poel was een belangrijke steunpilaar, 
zowel bij Sanquin als bij TRIP. Ook de andere leden van het Dagelijks Bestuur, te weten René de 
Vries, Fred Haas, Hans van Duijnhoven en Hans Soons, als ook mevrouw Eveline Six – Barones 
van Voorst tot Voorst de beschermvrouwe van de stichting, hebben mij gesteund door het 
vertrouwen in de positieve uitkomst, ook voor TRIP.
Speciale waardering wil ik uitspreken voor Tanneke Marijt-van der Kreek voor haar scherpe 
visie voor kwaliteit en verbetering van de donorzorg en voor haar inhoudelijke bijdrage. Mijn 
collega’s in de hemovigilantie Anita van Tilborgh-de Jong en Pauline Zijlker-Jansen hebben 
het leeuwendeel van de meldingen beoordeeld en ook meegedacht bij de gerapporteerde 
onderzoeken. Ingrid van Veen-Rottier, secretaresse van TRIP, verdient speciale dank voor 
haar bijdrage aan onder andere de secure gegevensverzameling. Ook lof en dank voor de 
secretaresses in Leiden, waaronder in het bijzonder Joke Bakker en Anne Cabenda. Zij waren 
er altijd voor mij. Anne-Marie van Walraven, Mariette Lenselink en Ivan Bank ben ik dankbaar 
voor de plezierige, gelukkig nog durende samenwerking in de stamcel donorstudie. Uiteraard 
hebben de vele co-auteurs ook hun bijdrage geleverd waarvoor dank. 
Mijn ouders ben ik dankbaar voor hun liefde en inspirerende voorbeelden. Ook heb ik van 
begin tot eind kunnen vertrouwen op de constante steun van mijn echtgenoot Tim en zonen 
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Peter en Andrew. Tim in het bijzonder heeft enorm meegeleefd en mij aangevuurd door alle 
ups en downs. 




Jo (Johanna) Wiersum-Osselton werd geboren op 4 december 1956 in Southampton, Engeland. 
Toen zij 12 jaar was verhuisde het gezin naar Leiden, waar zij haar schoolopleiding vervolgde 
aan het Stedelijk Gymnasium en in 1974 het eindexamen behaalde. In hetzelfde jaar ving zij 
de geneeskundestudie in Leiden aan; het doctoraalexamen werd in 1980 en het artsexamen 
in 1981 (cum laude) gehaald. Hierna werkte zij enkele jaren in Engeland, eerst als artsassistent 
in de spoedeisende hulp, interne geneeskunde en dermatologie. Na haar huwelijk en tussen 
de geboorten van de kinderen in 1984 en 1986 werkte zij parttime als polikliniekarts (clinical 
assistant) dermatologie tot 1988. Hierna werkten zij en haar echtgenoot Tim ruim vijf jaar in 
Conakry in de republiek Guinée in west-Afrika. Samen met Guineeërs zette zij een eerstelijns 
gezondheidsheidszorgpost op, die nog steeds draait. In 1996 trad zij in dienst bij Bloedbank 
Leidsenhage als donorarts en zij doet dit werk nog steeds, nu bij Sanquin Bloedvoorziening. De 
opleiding tot sociaal geneeskundige, tak algemene gezondheidszorg, werd in 2000 voltooid. 
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